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The isothiourea-catalysed chemo- and enantioselective [2,3]-sigmatropic rearrangement of N,N-
diallyl allylic ammonium ylides is explored as a key part of a route to free functionalised α-
amino esters and piperidines. The [2,3]-sigmatropic rearrangement proceeds with excellent 
diastereo- and enantiocontrol (>95:5 dr, up to 97% ee), with the resultant N,N-diallyl  α-amino 
esters undergoing either mono- or bis-N-allyl deprotection. Bis-N-allyl deprotection leads to free 
α-amino esters, while the mono-deprotection strategy has been utilised in the synthesis of a 
target functionalised piperidine. 
2009 Elsevier Ltd. All rights reserved.
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1. Introduction 
 [2,3]-Sigmatropic rearrangements are concerted symmetry 
allowed processes that proceed through a five-membered, six-
electron transition state with an envelope conformation. 
Stereoselective [2,3]-sigmatropic rearrangements have found 
great utility in organic synthesis,1 with their ability to form 
carbon-carbon bonds through well-defined and predictable 
transition states under often mild reaction conditions making 
them attractive for the synthesis of highly functionalised 
molecular building blocks.2  
In this context, the [2,3]-rearrangement of allylic ammonium 
ylides leads to the formation of substituted α-amino acid 
derivatives.  Initially investigated by Ollis,3 only limited variants 
of this process that use a sub-stoichiometric amount of a catalyst 
in the formation of the reactive ylide have been explored to 
date.1e The most common approach utilizes an intermediate metal 
carbenoid to generate the reactive ylide intermediate as shown by 
Doyle (Scheme 1a),4 yet catalytic enantioselective variants have 
remained elusive.1b  In 2011, Tambar and co-workers5 reported 
an alternative strategy in the catalytic [2,3]-rearrangements of 
allylic ammonium ylides through Pd-catalysed allylic substitution 
of allylic carbonates 5 with tertiary amino esters 4 and in situ 
rearrangement (Scheme 1b). This process generates 
functionalized α-amino esters 6 with high diastereocontrol but in 
racemic form.5 Building upon this work, we demonstrated an 
isothiourea-promoted6,7 catalytic enantioselective [2,3]-
rearrangement of allylic ammonium ylides, leading to a range of 
α-amino acid derivatives 8 bearing either N,N-dimethyl or cyclic-
N-alkyl substituents (Scheme 1c).8 This process allows for the 
synthesis of a variety of α-amino ester derivatives and the 
incorporation of pharmacological relevant amine motifs such as 
the morpholine unit, although the preparation of free α-amino 
esters was not possible as suitable N-substituents amenable to 
facile deprotection were not incorporated.  
 
Scheme 1: Catalytic stereoselective [2,3]-rearrangements of 
allylic ammonium ylides 
 
In this manuscript this limitation is addressed through the 
application of this methodology to N-substituents amenable to 
either mono- or bis-N-deprotection. At the onset of these 
investigations, the use of N,N-dibenzyl, N-methyl-N-allyl-, and 
N,N-diallyl substituents were considered to allow N-deprotection 
under standard laboratory conditions. Sweeney and Coldham 
have independently utilized N,N-diallyl groups in the synthesis of 
α-amino acids, via base mediated [2,3]-rearrangement and 
subsequent N-deprotection.9 Notable previous work by Tambar 
has shown that treatment of N-methyl-N-allyl amine 9 with 
cinnamyl carbonate 10 in the presence of Pd2(dba)3·CHCl3, P(2-
furyl)3 and Cs2CO3 gave ammonium ylide 11, bearing a 
stereogenic nitrogen.5 [2,3]-Rearrangement of ammonium ylide 
11 proceeded through the N-cinnamyl unit and the N-allyl unit, 
resulting in non-chemoselective [2,3]-rearrangement to give a 4:1 
mixture of N-cinnamyl rearranged product 12 and N-allyl 
rearranged product 13 in a combined 78% yield (Scheme 2a).5 
We report herein that isothiourea-mediated catalysis of N,N-
diallyl allylic ammonium ylides proceeds chemoselectively, 
generating N,N-diallyl amino esters 15 with high diastereo- and 
enantiocontrol that can be readily bis-deprotected to generate free 
α-amino esters (Scheme 2b). Mono-N-allyl deprotection, 
followed by metathesis, leads to valuable piperidine building 
blocks. 
 
Scheme 2: Proposed chemoselective [2,3]-rearrangement of 
N,N-diallyl allylic ammonium ylides. 
2. Results and Discussion 
Initial Studies and Optimisation  
To avoid any potential chemoselectivity issues initial studies 
probed the use of N,N-dibenzyl substituents in the isothiourea-
catalysed [2,3]-rearrangement methodology. Treatment of N,N-
dibenzyl cinnamyl amine 16 with 4-nitrophenyl bromoacetate 17 
resulted in no ammonium salt formation, presumably due to the 
sterically hindered N,N-dibenzyl substituent. To reduce the steric 
bulk around the N-substituent, an N-methyl-N-benzyl substitution 
was employed 18. While the corresponding ammonium salt could 
not be isolated, in situ ammonium salt formation and subsequent 
[2,3]-rearrangement gave, after treatment with sodium 
methoxide, N-methyl-N-benzyl-α-amino ester 20 in good yield 
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(76%) but modest stereocontrol (80:20 dr, 76% ee). The modest 
stereocontrol is likely to be due to the formation of a stereogenic 
nitrogen within the presumed ammonium salt and (+)-BTM 
bound-diastereoisomeric ammonium ylides within the [2,3]-
rearrangement step. Due to the low sterecontrol achieved with an 
unsymmetrical N,N-substituent, symmetrical N,N-diallyl 
substitution was investigated. Treatment of N,N-diallyl cinnamyl 
amine with 4-nitrophenyl bromoacetate 17 gave the 
corresponding quaternary ammonium salt 21 in 50% isolated 
yield (Scheme 3). Isothiourea-promoted rearrangement of 21, 
followed by addition of sodium ethoxide, resulted in 
chemoselective [2,3]-rearrangement to give N,N-diallyl-α-amino 
ester 22 in excellent yield (91%) and good stereocontrol (92:8 dr, 
87% ee).  
 
aIsolated yield, bIsolated as a mixture of diastereoisomers, cDetermined by 
1H NMR analysis of crude material, dDetermined by HPLC analysis on chiral 
stationary phase. 
Scheme 3: Evaluation of alternative N-substituents. 
 
Further optimisation was performed to improve the 
stereocontrol of the process (Table 1). The requirement for the 
HOBt co-catalyst was examined, with rearrangement in the 
absence of HOBt resulting in reduced product yield and 
stereocontrol (81%, 89:11 dr, 76% ee, entry 2, table 1). The use 
of a stoichiometric amount of NBu4OPNP as an additive also 
resulted in a loss in both diastereo- and enantiocontrol (88:12 dr, 
74% ee, entry 3). However, the use of stoichiometric HOBt as an 
additive resulted in a dramatic enhancement in enantiocontrol 
(82%, 94:6 dr, 97% ee, entry 4, table 1). In this process, we 
postulate that HOBt aids catalyst turnover from an acyl 
ammonium intermediate after [2,3]-rearrangement, although the 
reason for enhanced enantiocontrol is not clear and is the subject 
of ongoing mechanistic investigations. These optimized 
conditions were taken forward to examine the substrate scope of 
the reaction. Notably this process could be readily performed on 
a reasonable laboratory scale without erosion of stereocontrol, 
with 479 mg (1.60 mmol) of ethyl ester 22 (76% isolated yield) 
being generated from 1.0 g of N,N-diallyl ammonium salt 21 
(entry 5). 
 
Entrya Additive (mol%) Yield(%)b drc ee (%)d 
1 HOBt (20) 91 92:8 87 
2 - 81 89:11 76 
3 NBu4OPNP (100) 77 88:12 74 
4 HOBt (100) 82 94:6 97 
5e HOBt (100) 76 >95:5 97 
aReactions performed on 0.24 mmol scale, bIsolated yield after flash column 
chromatography, combined yield of mixture of diastereomers, cDetermined 
by 1H NMR of crude material, dDetermined by HPLC analysis on chiral 
stationary phase, ePerformed on 2.11 mmol scale. 
Table 1: Reaction additive optimization. 
 
The relative and absolute configuration within 22 was 
assigned by analogy to that previously unambiguously 
determined on an N,N-dimethyl substituted analogue. This 
configurational outcome is consistent with a Lewis base mediated 
mechanism involving enantioselective [2,3]-rearrangement that 
occurs through a BTM-bound intermediate ylide 24 via an endo-
type pre-transition state assembly such as 25. In this arrangement 
the carbonyl oxygen preferentially adopts a coplanar and syn-
orientation to the S atom within the isothiouronium ion, allowing 
a stabilizing electrostatic or non-bonding O-S interaction (nO to 
σ*C-S).10,11 The stereodirecting C(2)-phenyl unit within BTM 
adopts a pseudoaxial position to minimize 1,2-steric interactions, 
with rearrangement occurring anti to this substituent. A π-cation 
interaction between the allylic C(3)-phenyl substituent and the 
acyl ammonium ion provides an additional interaction that is 
essential for high stereocontrol (Figure 1). 
 
Figure 1: Stereochemical Rationale. 
 
Reaction Scope and N,N-diallyl deprotection 
With these optimised conditions in hand, the scope of in situ 
nucleophilic derivatization was examined. The [2,3]-
rearrangement of N,N-diallyl ammonium salt 21 could be 
derivatised in situ using pyrrolidine or LiAlH4 to give amide 27 
and amino-alcohol 28 respectively in excellent yield and 
stereocontrol (Scheme 4). However, using 100 mol% HOBt in the 
catalysis followed by derivatization with benzylamine to give 29, 
produced inseparable unidentified allyl-derived side products. 
However, the use of a catalytic amount of HOBt (20 mol %) 
allowed the isolation of benzyl amide 29 in excellent yield with 
good levels of stereocontrol (92:8 dr, 84% ee).  
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aIsolated yield after flash column chromatography, combined yield of mixture 
of diastereomers bDetermined by 1H NMR of crude material, cDetermined by 
HPLC analysis on chiral stationary phase dReaction performed using HOBt 
(20 mol%). 
 
Scheme 4: Scope of in situ nucleophilic derivatization. 
 
Variation of the C(3)-substituent within the N,N-diallyl 
ammonium salt 15 was next investigated. Electron-neutral and 
electron-withdrawing aromatic substituents could be well 
tolerated giving ethyl esters 31, 32 and 34 in excellent yield and 
good to excellent stereocontrol. Incorporation of a sterically 
demanding ortho-substituent in the C(3)-aryl group was well 
tolerated giving 33 in good yield and stereocontrol (Scheme 5). 
 
aIsolated yield after flash column chromatography, combined yield of mixture 
of diastereomers bDetermined by 1H NMR of crude material, cDetermined by 
HPLC analysis on chiral stationary phase, dEnantiopurity determined after 
N,N-deallylation and N-Boc protection. 
Scheme 5: Scope of C(3)-substituent. aEnantiopurity 
determined after N,N-deallylation and N-Boc protection. 
 
With a range of N,N-diallyl ethyl esters in hand, efforts were 
turned to removal of the N,N-diallyl groups to synthesise a range 
of α-amino esters. Utilising the Pd-catalysed deallylation 
chemistry developed by Bernard and co-workers12 treatment of 
22 with Pd(dba)2 (10 mol%), dppb (1,4 
bis(diphenylphosphino)butane) (10 mol%) and thiosalicylic acid 
(5.0 equiv.) in THF at 60 °C followed by aq. 1 M HCl allowed 
facile isolation of the desired free amine 36 as its hydrochloride 
salt,13 in excellent yield and without erosion of stereochemical 
purity, without the need for flash column chromatography. This 
was applied to a small range of N,N-diallyl rearrangement 
products 31-33 giving the desired deallylation products 37-39 in 
good to excellent yield without erosion of diastereo- or 
enantiopurity (Scheme 6).14 The relative and absolute 
configurations of the bis-deallylated products was confirmed 
through derivatization of 36 to the known corresponding N-
acetamide.15 
 
aIsolated yield, bDetermined by 1H NMR analysis, cDetermined by HPLC 
analysis on chiral stationary phase after filtration through K2CO3 plug, d 
cDetermined by HPLC analysis on chiral stationary phase after N-Boc 
protection. 
Scheme 6: Scope of N,N-deallylation of [2,3]-rearrangement 
products, aEnantiopurity determined after N-Boc protection. 
 
Application to piperidine synthesis 
To further demonstrate the synthetic utility of this [2,3]-
rearrangement process, it was postulated that a highly 
functionalised piperdine architecture could be accessed through 
selective mono-N-allyl deprotection, followed by ring-closing 
metathesis and hydrogenation. Piperidine core structures are 
ubiquitous among bioactive molecules,16 with an analysis of 
launched drugs within the integrity database showing 320 
registered drugs that contain piperidines.17 For example, the 
piperidine motif is central to Merck’s factor XIa inhibitor 40.18 
To showcase the utility of this [2,3]-rearrangement methodology 
we next targeted the preparation of the (2S,3S)-piperidine 2-
carboxylate 41 that maps directly to this core structure. 
 
Figure 2: Merck Factor XIa inhibitor and target (2S,3S)-
piperidine 2-carboxylate 41 
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Mono-deallylation of 22 following Bernard’s methodology,12 
through treatment with Pd(dba)2 (10 mol %), dppb (10 mol %), 
thiosalicylic acid (1.2 equiv.) in THF at 60 °C, gave 42 in modest 
yield (46% yield) but with retention of diastereomeric purity. 
Subsequent N-benzyl protection to give 43, followed by 
treatment with Hoveyda-Grubbs 2nd generation catalyst (HG-II) 
(5 mol%) in the presence of p-toluenesulfonic acid19 (1.5 equiv.) 
in toluene at 80 °C gave ring-closed product 44 in good yield and 
as a single diastereoisomer after purification. Finally, treatment 
of 44 with Pd/C and H2 resulted in hydrogenation and 
hydrogenolysis to give functionalised piperidine 45 in good yield 
and with excellent levels of stereocontrol (>95:5 dr, 94% ee).   
 
aIsolated yield, bDetermined by 1H NMR analysis after flash coloumn 
chromatography, cDetermined by HPLC analysis on chiral stationary phase. 
 
Scheme 7: Mono-N-deallylation and synthesis of a target 
functionalized (2S,3S) piperidine motif. 
3. Conclusions 
The isothiourea-catalysed enantioselective [2,3]-
rearrangement of N,N-diallyl cinnamic ammonium ylides 
proceeds chemoselectivity and with excellent enantioselectivity. 
The use of stoichiometric HOBt allowed excellent levels of 
diastereo- and enantiocontrol to be achieved (up to >95:5 dr, up 
to 97% ee). The substrate scope of this process has been 
examined across a small number of different aryl and nucleophile 
variations. The N,N-diallyl substituents can be readily removed to 
generate the parent free α-amino ester, and this methodology has 
been applied to the synthesis of a functionalised target piperdine 
motif.  
4. Experimental Section 
Reactions were performed in flame-dried glassware under an N2 
atmosphere unless otherwise stated. Anhydrous CH2Cl2 and Et2O 
were obtained from an MBraun SPS-800 system, MeCN was 
HPLC grade stored over 4 Å MS. All other solvents and 
commercial reagents were used as received without further 
purification unless otherwise stated. Room temperature (rt) refers 
to 20-25 °C. Temperatures of 0 °C, −20 °C and −78 °C were 
obtained using ice/water bath, an immersion cooler and 
CO2(s)/acetone bath, respectively. Analytical thin layer 
chromatography was performed on pre-coated aluminium plates 
(Kieselgel 60 F254 silica). Plates were visualised under UV light 
(254 nm) or by staining with either phosphomolybdic acid or 
KMnO4 followed by heating. Flash column chromatography was 
performed on Kieselgel 60 silica in the solvent system stated. 
Melting points were recorded on an Electrothermal 9100 melting 
point apparatus, dec refers to decomposition. Optical rotations 
were measured on a Perkin Elmer Precisely/Model-341 
polarimeter operating at the sodium D line with a 100 mm path 
cell at 20 °C. HPLC analyses were obtained on a Shimadzu 
HPLC consisting of a DGU-20A5 degasser, LC-20AT liquid 
chromatography SIL-20AHT autosampler, CMB-20A 
communications bus module, SPD-M20A diode array detector 
and a CTO-20A column oven that allows the temperature to be 
set from 25-40 °C. Separation was achieved using a Chiralcel OJ-
H, or Chiralpak AD-H, AS-H, IA, IB, and ID columns. The 
columns were flushed with 40% IPA/hexane for 15 mins before 
switching to the indicated solvent mixtures, as this ensured 
reproducibility of chromatograms. Infrared spectra (νmax) were 
recorded on a Shimadzu IRAffinity-1 Fourier transform IR 
spectrophotometer using either thin film or solid using Pike 
MIRacle ATR accessory. Analysis was carried out using 
Shimadzu IRsolution v1.50 and only characteristic peaks are 
reported. 1H, 13C{1H}, 19F{1H} and 19F NMR spectra were 
acquired on either a Bruker Avance 300 {δH (300 MHz), δC (75 
MHz), δF (282 MHz)}, a Bruker Avance II 400 {δH (400 MHz), 
δC (100 MHz), δF (376 MHz)}, a Bruker Ultrashield 500 {δH (500 
MHz), δC (126 MHz), δF (471 MHz)}, a Bruker Ascend 400 {δH 
400 MHz, δC (100 MHz), δF (471 MHz)} or a Bruker Avace III 
700 {δH (700 MHz), δC (179 MHz), δF (659 MHz)} spectrometer 
at ambient temperature (unless otherwise stated) in the deuterated 
solvent stated. Chemical shifts, δ, are quoted in parts per million 
(ppm) and are referenced to the residual solvent peak. Coupling 
constants, J, are quoted in Hertz (Hz) to the nearest 0.1 Hz. The 
following abbreviations are used: s, singlet; d, doublet; t, triplet; 
q, quartet; dd, doublet of doublets; ddd, doublet of doublet of 
doublets; dt, doublet of triplets; ddt, doublet of doublets of 
triplets; dtt, doublet of triplets of triplets; dq, doublet of quartets; 
td, triplet of doublets; tdd, triplet of triplets of doublets; tt, triplet 
of triplets; m, multiplet; br, broad; and apt, apparent. Mass 
spectrometry (HRMS) data were acquired by electrospray 
ionisation (ESI), electron impact (EI), chemical ionisation (CI), 
atmospheric pressure chemical ionisation (APCI) or nanospray 
ionisation (NSI) at the EPSRC UK National Mass Spectrometry 
Facility at Swansea University.  
 
Isothiourea Catalysts; (+)-BTM and (±)-BTM were synthesised 
according to literature procedures.20 Allylic Alcohols 4-
nitrocinnamyl alcohol, 4-bromocinnamyl alcohol, 2-
bromocinnamyl alcohol and 4-fluorocinnamyl alcohol were 
synthesised according to previously reported procedure.6 
 
Authentic racemic samples of the [2,3]-rearrangement products 
22, 27-29 and 31-34 were synthesised using (±)-BTM. 
 
(E)-N,N-Dibenzyl-3-phenylprop-2-en-1-amine 16 
 
A solution of N,N-dibenzylamine (6.1 mL, 31.7 mmol, 2.5 
equiv.) in THF (12.5 mL) was treated dropwise with a solution of 
cinnamyl bromide (2.5 g, 12.7 mmol, 1.0 equiv.) in THF (26 mL) 
over 10 mins at rt. The resulting mixture for stirred for 16 h, aq. 1 
M NaOH (30 mL) was added and the mixture stirred for a further 
5 min, Et2O (30 mL) was then added, the layers separated and the 
aqueous layer extracted with Et2O (2 × 50 mL). The combined 
organic layers were washed with brine (50 mL) dried over 
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MgSO4 and concentrated in vacuo, the resulting residue was 
purified by flash column chromatography (5-20% EtOAc/PE) to 
give the title product as a yellow oil (4.23 g, quant., >98:2 E:Z); 
1H NMR (500 MHz, CDCl3) δH 3.24 (2H, dd, J 6.5, 1.5, C(1)H2), 
3.64 (4H, s, PhCH2), 6.24-6.38 (1H, m, C(2)H), 6.54 (1H, d, J 
16.0, C(3)H), 7.14-7.49 (15H, m, ArH); data consistent with 
literature.21 
 
(E)-N-Benzyl-N-methyl-3-phenylprop-2-en-1-amine 18 
 
A solution of N-benzyl-N-methylamine (8.2 mL, 63.5 mmol, 2.5 
equiv.) in THF (26 mL) was treated dropwise with a solution of 
cinnamyl bromide (5.0 g, 25.4 mmol, 1.0 equiv.) in THF (50 mL) 
over 10 mins at rt. The resulting mixture was stirred for a further 
15 mins, aq. 1 M NaOH (50 mL) added and the mixture stirred 
for a further 5 min, Et2O (50 mL) was then added, the layers 
separated and the aqueous layer extracted with Et2O (2 × 50 mL). 
The combined organic layers were washed with brine (50 mL) 
dried over MgSO4 and concentrated in vacuo, the resulting 
residue was purified by flash column chromatography (5-20% 
EtOAc/PE) to give the title product as an orange oil (5.2 g, 86%, 
98:2 E:Z); 1H NMR (500 MHz, CDCl3) δH 2.28 (3H, s, NCH3), 
3.23 (2H, dd, J 6.7, 1.5, C(1)H2), 3.58 (2H, s, PhCH2), 6.36 (1H, 
dt, J 15.9, 6.7, C(2)H), 6.57 (1H, dd, J 15.9, 1.5, C(3)H), 7.20-
7.47 (10H, m, ArH); data consistent with literature.22 
 
Methyl (2S,3S)-2-(benzyl(methyl)amino)-3-phenylpent-4-
enoate 20 
 
A solution of 4-nitrophenyl-2-bromoacetate (63 mg, 0.24 mmol, 
1.0 equiv.) and (E)-N-Benzyl-N-methyl-3-phenylprop-2-en-1-
amine (60 mg, 0.252 mmol, 1.05 equiv.) in MeCN (1.75 mL) was 
stirred for 24 h at rt, then cooled to −20 °C and a solution of (+)-
BTM (12 mg, 0.048 mmol, 0.2 equiv.), HOBt (6.4 mg, 0.048 
mmol, 0.2 equiv.) and iPr2NH (47 µL, 0.34 mmol, 1.4 equiv.) in 
MeCN (1.75 mL) was added and the reaction sitrred for 24 h at 
−20 °C, then quenched with NaOMe (1 M in MeOH, 0.72 mL, 
0.72 mmol, 3.0 equiv.) and stirred at rt for 1 h. Aq. 1 M NaOH 
(10 mL) was added and the mixture extracted with CH2Cl2 (3 × 
20 mL), the combined organic layers were washed with aq. 1 M 
NaOH (2 × 20 mL), then brine (20 mL), dried over MgSO4 and 
concentration in vacuo. Crude dr 80:20, the residue was purified 
by flash column chromatography (5% EtOAc/PE) to give the title 
product as a colourless oil (56 mg, 76%, 80:20 dr); Chiralpak OJ-
H (0.5% IPA/hexane, flow rate 1.5 mL/min, 211 nm, 40 °C) tR 
Major 9.5 min, Minor 6.9 min, 76% ee; [α] −5.7 (c 1, CHCl3); 
υmax (film, cm−1) 2949, 1728, 1452, 1254, 1190, 1146, 1026, 984, 
918; Major (Syn) diastereoisomer; 1H NMR (500 MHz, CDCl3) 
δH 2.15 (3H, s, NCH3), 3.39 (1H, d, J 13.7, PhCHH), 3.70 (1H, d, 
J 11.8, C(2)H), 3.75 (1H, d, J 13.7, PhCHH), 3.77 (3H, s, OCH3), 
3.87 (1H, dd, J 11.8, 8.3, C(3)H), 4.94-5.12 (2H, m, C(5)H2), 
5.85 (1H, ddd, J 17.1, 10.2, 8.3, C(4)H), 6.69-6.86 (2H, m, ArH), 
7.10-7.21 (5H, m, ArH), 7.22-7.40 (3H, m, ArH); 13C{1H} NMR 
(126 MHz, CDCl3) δC 38.1 (NCH3), 50.2 (C(3)H), 51.0 (C(2)H), 
58.2 (PhCH2), 69.4 (OCH3), 116.7 (C(5)H2), 126.6 (ArCH), 
126.9 (ArCH), 128.1 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 
128.7 (ArCH), 138.8 (C(4)H), 139.2 (ArC), 140.7 (ArC), 171.4 
(C=O); Minor (Anti) diastereoisomer; 1H NMR (500 MHz, 
CDCl3) δH 2.29 (3H, s, NCH3), 3.48 (3H, s, OCH3), 3.51 (1H, d, J 
13.6, PhCHH), 3.68 (1H, d, J 11.6, C(2)H)), 3.75 (1H, d, J 13.6 
PhCHH), 3.83-3.94 (1H, m, C(3)H), 5.04-5.10 (2H, m, C(5)H2), 
6.20 (1H, ddd, J 17.2, 10.2, 8.2, C(4)H), 6.69-6.86 (2H, m, ArH), 
7.10-7.21 (5H, m, ArH), 7.22-7.40 (3H, m, ArH); 13C{1H} NMR 
(126 MHz, CDCl3) δC 38.1 (NCH3), 49.6 (C(3)H), 50.8 (C(2)H), 
58.3 (PhCH2), 70.5 (OCH3), 116.1 (C(5)H2), 126.9 (ArCH), 
127.1 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.7 (ArCH), 
128.9 (ArCH), 138.8 (C(4)H), 139.4 (ArC), 141.1 (ArC), 170.6 
(C=O); HRMS (ESI+) C20H24O2N+ [M+H]+ found: 310.1794, 
requires: 310.1802 (−2.6 ppm). 
 
General Procedure A: Synthesis of N,N-diallylamines from 
Allylic Alcohols 
 
A solution of allylic alcohol (1.0 equiv.) in Et2O (0.33 M) was 
cooled to 0 °C and treated with PBr3 (0.4 equiv.) and stirred for 1 
h, the reaction was quenched by the dropwise addition of aq. sat. 
NaHCO3 (equal volume), the mixture was allowed to warm to rt. 
The layers were then separated, the aqueous layer extracted with 
Et2O (2 × equal volume), the combined organic layers washed 
with brine, dried over MgSO4 and concentrated in vacuo. The 
residue was dissolved in THF (0.5 M) and added to N,N-
diallylamine (2.5 equiv.) in THF (2.5 M with respect to N,N-
diallylamine) via dropping funnel , upon completion the dropping 
funnel was rinsed with THF (half volume) and the reaction was 
stirred at rt for 15 min. The reaction was treated with aq. 1 M 
NaOH (equal volume) and stirred for 15 min, then Et2O (equal 
volume) was added, the layers separated and the aqueous layer 
extracted with Et2O (2 × equal volume). The combined organic 
layers were washed with brine, dried over MgSO4 then 
concentrated in vacuo, N,N-diallyl allylic amines were used 
without further purification.  
 
General Procedure B: Synthesis of N,N diallyl allylic 
ammonium salts 
 
A solution of N,N-diallyl amine (1.0 equiv.) in MeCN (1 M) was 
treated with 4-nitrophenyl bromoacetate (1.2 equiv.) and the 
reaction mixture was stirred for 16 h. Et2O (5 × volume) was 
added and the mixture stirred for 1-16 h, the precipitate was 
filtered and dried in vacuo to give the salts. Ammonium salts 
were used directly or recrystallized from MeCN/Et2O if required.  
 
Amine Synthesis 
 
(E)-N,N-Diallyl-3-phenylprop-2-en-1-amine 46 
 
A solution of cinnamyl bromide (25.0 g, 126.9 mmol, 1.0 equiv.) 
in THF (250 mL) was added dropwise to a solution of N,N-
diallylamine (39.1 mL, 317.0 mmol, 2.5 equiv.) in THF (125 mL) 
dropwise over 10 min at rt. The resulting solution was stirred at rt 
for a further 15 min. aq. 1 M NaOH (200 mL) was then added and 
the mixture stirred for a further 5 min, Et2O (200 mL) was then 
added, the layers separated and the aqueous layer extracted with 
Et2O (2 × 200 mL). The combined organic layers were washed 
with brine (200 mL) dried over MgSO4 and concentrated in 
vacuo, the resulting residue was purified by high vacuum 
distillation to give the title product as a colourless liquid (25.2 g, 
93%); bp 136-138 °C @ 1mmbar; υmax (film, cm−1) 2800, 1641, 
1494, 1448, 1417, 1352, 1119, 995, 964, 916, 873; 1H NMR (500 
MHz, CDCl3) δH 3.17 (4H, d, J 6.5, diallyl-C(1)H2), 3.28 (2H, d, 
J 6.7, C(1)H2), 5.13-5.27 (4H, m, diallyl-C(3)H2), 5.92 (2H, ddt, 
J 16.8, 10.2, 6.5, diallyl-C(2)H), 6.29 (1H, dt, J 15.8, 6.7, 
C(2)H), 6.54 (1H, d, J 15.8, C(3)H), 7.22-7.44 (5H, m, ArH); 
13C{1H} NMR (75 MHz, CDCl3) δC 55.8 (C(1)H2), 56.6 (diallyl-
C(1)H2), 117.7 (diallyl-C(5)H2), 126.3 (ArC(2,6)H), 127.3 
(ArC(4)H), 127.4 (C(2)H), 128.6 (ArC(3,5)H), 132.7 (C(3)H), 
135.6 (diallyl-C(2)H), 137.1 (ArC(1)); HRMS (ESI+) C15H20N+ 
[M+H]+ found: 214.1590, requires: 214.1590 (−0.1 ppm). 
 
 
(E)-N,N-diallyl-3-(4-nitrophenyl)prop-2-en-1-amine 47 
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Following general procedure A, 4-nitrocinnamyl alcohol (2.86 g, 
15.98 mmol, 1.0 equiv.) was reacted with PBr3 (601 µL, 6.39 
mmol, 0.4 equiv.) in Et2O (48 mL), then with N,N-diallylamine 
(4.93 mL, 40 mmol, 2.5 equiv.) in THF (32 mL) to give the title 
product as an orange oil (2.63 g, 64%) was used without further 
purification; υmax (film, cm−1) 2978, 1595, 1512, 1339, 1109, 968, 
918, 858; 1H NMR (400 MHz, CDCl3) δH 3.14 (4H, d, J 6.5, 
diallyl-C(1)H2), 3.28 (2H, dd, J 6.3, 1.4, C(1)H2), 5.12-5.25 (4H, 
m, diallyl-C(3)H2), 5.88 (2H, ddt, J 16.8, 10.2, 6.5, diallyl-
C(2)H), 6.45 (1H, dt, J 15.9, 6.3, C(2)H), 6.59 (1H, d, J 15.9, 
C(3)H), 7.48 (2H, d, J 8.8, Ar(2,6)H), 8.17 (2H, d, J 8.8, 
Ar(3,5)H); 13C{1H} NMR (100 MHz, CDCl3) δC 55.5 (C(1)H2), 
56.8 (diallyl-C(1)H2), 117.9 (diallyl-C(3)H2), 124.0 (ArC(3,5)H), 
126.7 (ArC(2,6)H), 130.3 (C(2)H), 133.1 (C(3)H, 135.3 (diallyl-
C(2)H), 143.6 (ArC(1)), 146.8 (ArC(4)-NO2); HRMS (ESI+) 
C15H19O2N2+ [M+H]+ found: 259.1440, requires: 259.1447 (−2.7 
ppm). 
 
(E)-N,N-diallyl-3-(4-bromophenyl)prop-2-en-1-amine 48 
 
Following general procedure A, 4-bromocinnamyl alcohol (1.62 
g, 7.59 mmol, 1.0 equiv.) was reacted with PBr3 (286 µL, 3.04 
mmol, 0.4 equiv.) in Et2O (24 mL), then with N,N-diallylamine 
(2.53 mL, 18.97 mmol, 2.5 equiv.) in THF (16 mL) to give the 
title product as a pale yellow oil (0.99 g, 45%) was used without 
further purification; υmax (film, cm−1) 2976, 1487, 1400, 1072, 
1009, 968, 918; 1H NMR (400 MHz, CDCl3) δH 3.12 (4H, dt, J 
6.5, 1.3, diallyl-C(1)H2), 3.22 (2H, dd, J 6.6, 1.4, C(1)H2), 5.09-
5.25 (4H, m, diallyl-C(3)H2), 5.87 (2H, ddt, J 16.8, 10.2, 6.5, 
diallyl-C(2)H), 6.25 (1H, dt, J 15.9, 6.6, C(2)H), 6.45 (dt, J 15.9, 
1.4, C(3)H), 7.23 (2H, d, J 8.5, Ar(2,6)H), 7.42 (2H, d, J 8.5, 
Ar(3,5)H); 13C{1H} NMR (100 Mz, CDCl3) δC 55.8 (C(1)H2), 
56.8 (diallyl-C(1)H2), 117.9 (diallyl-C(3)H2), 121.2 (ArC(4)-Br), 
127.9 (ArC(2,6)H), 128.5 (C(2)H), 131.5 (C(3)H), 131.8 
(ArC(3,5)H), 135.6 (diallyl-C(2)H), 136.2 (ArC(1)); HRMS 
(ESI+) C15H19N79Br+ [M+H]+ found: 292.0694, requires: 
292.0701 (−2.4 ppm). 
 
(E)-N,N-diallyl-3-(2-bromophenyl)prop-2-en-1-amine 49 
 
Following general procedure A, 2-bromocinnamyl alcohol (1.36 
g, 6.37 mmol, 1.0 equiv.) was reacted with PBr3 (240 µL, 2.55 
mmol, 0.4 equiv.) in Et2O (20 mL), then with N,N-diallylamine 
(1.96 mL, 15.93 mmol, 2.5 equiv.) in THF (13 mL) to give the 
title product as a pale yellow oil (1.10 g, 59%) was used without 
further purification; υmax (film, cm−1) 2976, 1643, 1466, 1435, 
1256, 1113, 1047, 1022, 966, 918; 1H NMR (400 MHz, CDCl3) 
δH 3.15 (4H, dt, J 6.5, 1.3, diallyl-C(1)H2), 3.29 (2H, dd, J 6.7, 
1.5, C(1)H2), 5.11-5.27 (4H, m, diallyl-C(3)H2), 5.89 (2H, ddt, J 
16.8, 10.2, 6.5, diallyl-C(2)H), 6.19 (1H, dt, J 15.8, 6.7, C(2)H), 
6.86 (1H, d, J 15.8, C(3)H), 7.08 (1H, td, J 7.7, 1.6, Ar(6)H), 
7.19-7.32 (1H, m, Ar(5)H), 7.53 (2H, td, J 8.0, 1.6, Ar(3,4)H); 
13C{1H} NMR (100 Mz, CDCl3) δC 55.7 (C(1)H2), 56.7 (diallyl-
C(1)H2), 118.0 (diallyl-C(3)H2), 123.5 (ArC(2)-Br), 127.2 
(ArC(4)H), 127.6 (ArC(5)H), 128.8 (ArC(6)H), 130.6 (C(2)H), 
131.6 (C(2)H), 133.0 (ArC(3)H), 135.6 (diallyl-C(2)H), 137.2 
(ArC(1)); HRMS (ESI+) C15H19N79Br+ [M+H]+ found: 292.0694, 
requires: 292.0701 (−2.4 ppm). 
 
(E)-N,N-diallyl-3-(4-fluorophenyl)prop-2-en-1-amine 50 
 
Following general procedure A, 4-fluorocinnamyl alcohol (1.36 
g, 6.37 mmol, 1.0 equiv.) was reacted with PBr3 (240 µL, 2.55 
mmol, 0.4 equiv.) in Et2O (20 mL), then with N,N-diallylamine 
(1.96 mL, 15.93 mmol, 2.5 equiv.) in THF (13 mL) to give the 
title product as a pale yellow oil (1.10 g, 59%, 96:4 E:Z) was 
used without further purification; υmax (film, cm−1) 2918, 2803, 
1603, 1508, 1227, 1157, 1119, 966, 917, 841; 1H NMR (400 
MHz, CDCl3) δH 3.13 (4H, dt, J 6.5, 1.3, diallyl-C(1)H2), 3.23 
(2H, dd, J 6.7, 1.4, C(1)H2), 5.12-5.28 (4H, m, diallyl-C(3)H2), 
5.88 (2H, ddt, J 16.8, 10.2, 6.5, diallyl-C(2)H), 6.17 (1H, dt, J 
15.8, 6.7, C(2)H), 6.47 (1H, dt, J 15.8, 1.4, C(2)H), 6.89-7.07 
(2H, m, Ar(3,5)H), 7.28-7.37 (2H, m, Ar(2,6)H); 19F{1H} NMR 
(376 MHz, CDCl3) δF −114.9 (ArF); 13C{1H} NMR (100 Mz, 
CDCl3) δC 55.7 (C(1)H2), 56.6 (diallyl-C(1)H2), 115.4 (d, 2JCF 
21.5, ArC(3,5)H), 117.9 (diallyl-C(3)H2), 127.0 (C(2)H), 127.7 
(d, 3JCF 7.8, ArC(2,6)H), 131.5 (C(3)H), 131.9 (d, 4JCF 2.9, 
ArC(1)), 135.4 (diallyl-C(2)H), 162.2 (d, 1JCF 247, ArC(4)-F); 
HRMS (ESI+) C15H19NF+ [M+H]+ found: 232.1494, requires: 
232.1502 (−3.5 ppm). 
 
(E)-N,N-Diallyl-N-(2-(4-nitrophenoxy)-2-oxoethyl)-3-
phenylprop-2-en-1-ammonium bromide 21 
 
Following general procedure B: (E)-N,N-diallyl-3-(phenyl)prop-
2-en-1-amine (5.0 g, 23.47 mmol, 1.0 equiv.) was reacted with 4-
nitrophenyl bromoacetate (7.32 g, 28.17 mmol, 1.2 equiv.) in 
MeCN (23.5 mL) to give the title product as a white solid (5.54 
g, 50%); mp 128 °C (dec.); υmax (film, cm−1) 2945, 1771, 1616, 
1591, 1528, 1452, 1346, 1996, 166, 1142, 988, 937, 883; 1H 
NMR (500 MHz, d6-DMSO) δH  4.27 (4H, d, J 7.3, diallyl-
C(1)H2), 4.37 (2H, d, J 7.4, C(1)H2), 4.73 (2H, s, COCH2), 5.57-
5.89 (4H, m, diallyl-C(3)H2), 6.24 (2H, ddt, J 17.3, 10.0, 7.3, 
diallyl-C(2)H), 6.60 (1H, dt, J 15.5, 7.4, C(2)H), 7.03 (1H, d, J 
15.5, C(3)H), 7.34-7.46 (3H, m, ArH), 7.49 (2H, d, J 9.1, 
Ar(3,5)H), 7.56-7.68 (2H, m, ArH), 8.37 (2H, d, J 9.1, 
Ar(2,6)H); 13C{1H} NMR (126 MHz, d6-DMSO) δC 56.2 
(COCH2), 62.3 (diallyl-C(1)H2), 62.5 (C(1)H2), 115.7 (C(2)H), 
123.0 ( rC(2,6)H), 125.4 (ArC(3,5)H), 125.6 (diallyl-C(3)H2), 
127.4 (C(3)ArC(2,6)H), 128.6 (diallyl-C(2)H), 128.8 
(C(3)ArC(3,5)H), 129.2 (C(3)ArC(4)H), 135.1 (C(3)ArC(1)), 
141.6 (C(3)H), 145.7 (ArC(1)-O), 153.7 (ArC(4)-NO2), 163.3 
(C=O); HRMS (ESI+) C23H25O4N2+ [M]+ found: 393.1801, 
requires: 393.1809 (−2.0 ppm). 
 
(E)-N,N-Diallyl-N-(2-(4-nitrophenoxy)-2-oxoethyl)-3-(4-
nitrophenyl)prop-2-en-1-ammonium bromide 51 
 
Following general procedure B: (E)-N,N-diallyl-3-(4-
nitrophenyl)prop-2-en-1-amine (1.0 g, 3.88 mmol, 1.0 equiv.) 
was reacted with 4-nitrophenyl bromoacetate (1.21 g, 4.66 mmol, 
1.2 equiv.) in MeCN (4 mL) to give the title product as a white 
solid (0.55 g, 28%) after recrystallization from MeCN; mp 142 
°C (dec.); υmax (film, cm−1) 2945, 1773, 1593, 1516, 1452, 1343, 
1197, 1167, 1069, 1012, 951, 880; 1H NMR (500 MHz, d6-
DMSO) δH 4.30 (4H, d, J 7.3, diallyl-C(1)H2), 4.43 (2H, d, J 7.4, 
C(1)H2), 4.77 (2H, s, COCH2), 5.71-5.84 (4H, m, diallyl-C(3)H2), 
6.24 (2H, ddt, diallyl-C(2)H), 6.87 (1H, dt, J 15.5, 7.4, C(2)H), 
7.17 (1H, d, J 15.5, C(3)H), 7.51 (2H, d, J 9.1, Ar(2,6)H), 7.92 
(2H, d, J 8.9, C(3)Ar(2,6)H), 8.29 (2H, d, J 8.9, C(3)Ar(3,5)H), 
8.38 (2H, d, J 9.1, Ar(3,5)H); 13C{1H} NMR (126 MHz, d6-
DMSO) δC 56.3 (COCH2), 61.9 (C(1)H2), 62.5 (diallyl-C(1)H2), 
120.9 (C(2)H), 123.0 (ArC(2,6)H), 123.9 (ArC(3,5)H), 125.3 
(diallyl-C(2)H), 125.6 (ArC(3,5)H), 128.5 (ArC(2,6)H), 128.8 
(diallyl-C(3)H2), 139.1 (C(3)H), 141.7 (C(3)ArC(4)-NO2), 145.7 
(ArC(1)-O), 147.4 (C(3)ArC(1)), 153.7 (ArC(4)-NO2), 163.2 
(C=O); HRMS (ESI+) C23H24O6N3+ [M]+ found: 438.1651, 
requires: 438.1660 (−2.1 ppm). 
 
(E)-N,N-Diallyl-3-(2-bromophenyl)-N-(2-(4-nitrophenoxy)-2-
oxoethyl)prop-2-en-1-ammonium bromide 52 
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Following general procedure B: (E)-N,N-diallyl-3-(2-
bromophenyl)prop-2-en-1-amine (1.1 g, 3.77 mmol, 1.0 equiv.) 
was reacted with 4-nitrophenyl bromoacetate (1.18 g, 4.53 mmol, 
1.2 equiv.) in MeCN (4 mL) to give the title product as a white 
solid (0.80 g, 39%) after recrystallization from MeCN; mp 98 °C 
(dec.); υmax (film, cm−1) 2954, 1773, 1525, 1348, 1201, 1168, 
1066, 1022, 943, 858; 1H NMR (400 MHz, d6-DMSO) δH 4.31 
(4H, d, J 7.2, diallyl-C(1)H2), 4.46 (2H, d, J 7.4, C(1)H2), 4.79 
(2H, s, COCH2), 5.65.-5.84 (4H, m, diallyl-C(3)H2), 6.24 (2H, 
ddd, J 17.0, 9.8, 5.3, diallyl-C(2)H), 6.62 (1H, dt, J 15.3, 7.4, 
C(2)H), 7.24 (1H, d, J 15.3, C(3)H), 7.33 (1H, t, J 7.6, Ar(4)H), 
7.47 (1H, t, J 7.7, Ar(5)H), 7.52 (2H, d, J 8.9, ArC(2,6)H), 7.69 
(1H, d, J 8.0, Ar(6)H), 7.96 (1H, d, J 7.8, Ar(3)H), 8.37 (2H, d, J 
8.9, ArC(3,5)H); 13C{1H} NMR (126 MHz, d6-DMSO) δC 56.2 
(COCH2), 62.0 (C(1)H2), 62.4 (diallyl-C(1)H2), 119.5 (C(2)H), 
123.0 (ArC(2,6)H), 123.3 (C(3)ArC(2)-Br), 125.4 (ArC(3,5)H), 
125.6 (diallyl-C(3)H2), 128.1 (C(3)ArC(4)H), 128.6 
(C(3)ArC(6)H), 128.6 (diallyl-C(2)H), 130.9 (C(3)ArC(5)H), 
132.9 (C(3)ArC(3)H), 134.8 (C(3)ArC(1)), 139.4 (C(3)H), 145.7 
(ArC(1)-O), 153.7 (ArC(4)-NO2), 163.2 (C=O); HRMS (ESI+) 
C23H24O4N279Br+ [M]+ found: 471.0904, requires: 471.0914 (−2.1 
ppm). 
 
(E)-N,N-Diallyl-3-(4-fluorophenyl)-N-(2-(4-nitrophenoxy)-2-
oxoethyl)prop-2-en-1-ammonium bromide 53 
 
Following general procedure B: (E)-N,N-diallyl-3-(4-
fluorophenyl)prop-2-en-1-amine (1.0 g, 4.33 mmol, 1.0 equiv.) 
was reacted with 4-nitrophenyl bromoacetate (1.35 g, 5.19 mmol, 
1.2 equiv.) in MeCN (4.3 mL) to give the title product as a white 
solid (1.23 g, 58%); mp 132 °C (dec.); υmax (film, cm−1) 2945, 
1771, 1591, 1528, 1348, 1200, 1159, 1141, 988, 939, 837; 1H 
NMR (500 MHz, d6-DMSO) δH 4.28 (4H, d, J 7.3, diallyl-
C(1)H2), 4.36 (2H, d, J 7.5, C(1)H2), 4.75 (2H, s, COCH2), 5.71-
5.82 (4H, m, diallyl-C(3)H2), 6.24 (2H, ddt, J 17.3, 10.1, 7.2, 
diallyl-C(2)H), 6.56 (1H, dt, J 15.5, 7.5, C(2)H), 7.02 (1H, d, J 
15.5, C(3)H), 7.27 (2H, t, J 8.8, Ar(3,5)H), 7.50 (2H, d, J 9.1, 
Ar(2,6)H), 7.71 (2H, dd, J 8.7, 5.7, Ar(2,6)H), 8.37 (2H, d, J 9.1, 
Ar(3,5)H); 19F NMR (476 MHz, d6-DMSO) δF −112.1 (ddt, J 
14.4, 9.0, 5.6, ArF); 13C{1H} NMR (126 MHz, d6-DMSO) δC 
56.2 (COCH2), 62.2 (diallyl-C(1)H2), 62.4 (C(1)H2), 115.6 (d, 
2JCF 21.4, ArC(3,5)H) + C(2)H), 123.0 (ArC(2,6)H), 125.4 
(ArC(3,5)H), 125.6 (diallyl-C(3)H), 128.6 (diallyl-C(2)H), 129.6 
(d, 3JCF 8.2, ArC(2,6)H), 131.8 (d, 4JCF 3.1, ArC(1)), 140.4 
(C(3)H), 145.7 (ArC(1)-O)), 153.7 (ArC(4)-NO2), 162.5 (d, 1JCF 
247, ArC(4)-F), 163.3 (C=O); HRMS (ESI+) C23H24O4N2F+ [M]+ 
found: 411.1708, requires: 411.1715 (−1.7 ppm). 
 
(E)-N,N-Diallyl-3-(4-bromophenyl)-N-(2-(4-nitrophenoxy)-2-
oxoethyl)prop-2-en-1-ammonium bromide 54 
 
Following general procedure B: (E)-N,N-diallyl-3-(4-
bromophenyl)prop-2-en-1-amine (0.99 g, 3.39 mmol, 1.0 equiv.) 
was reacted with 4-nitrophenyl bromoacetate (1.06 g, 4.06 mmol, 
1.2 equiv.) in MeCN (4 mL) to give the title product as a white 
solid (1.12 g, 60%); mp 126 °C (dec.); υmax (film, cm−1) 2943, 
1771, 1591, 1526, 1487, 1450, 1346, 1198, 1167, 1142, 939, 883; 
1H NMR (500 MHz, d6-DMSO) δH 4.26 (4H, d, J 7.3, diallyl-
C(1)H2), 4.35 (2H, d, J 7.4, C(1)H2), 4.73 (2H, s, COCH2), 5.68-
5.85 (4H, m, diallyl-C(3)H2), 6.12-6.31 (2H, m, diallyl-C(2)H), 
6.63 (1H, dt, J 15.5, 7.4, C(2)H), 6.99 (1H, d, J 15.5, C(3)H), 
7.49 (2H, d, J 9.1, Ar(2,6)H), 7.55-7.66 (4H, m, Ar(2,3,5,6)H), 
8.36 (2H, d, J 9.1, Ar(3,5)H); 13C {1H} NMR (126 MHz, d6-
DMSO) δC 56.2 (COCH2), 62.3 (C(1)H2), 62.3 (diallyl-C(1)H2), 
116.8 (C(2)H), 122.4 (ArC(4)-Br), 123.0 (ArC(2,6)H), 125.4 
(ArC(3,5)H), 125.6 (diallyl-C(3)H2), 128.7 (diallyl-C(2)H), 129.5 
(ArC(2,6)H), 131.7 (ArC(3,5)H), 134.4 (C(3)ArC(1)), 140.2 
(C(3)H), 145.7 (ArC(1)-O), 153.7 (ArC(4)-NO2), 163.3 (C=O); 
HRMS (ESI+) C23H24O4N279Br+ [M]+ found: 471.0904, requires: 
471.0914 (−2.1 ppm). 
 
[2,3]-Rearrangement Products 
 
General Procedure C: Catalytic asymmetric [2,3]-
rearrangement of N,N-diallyl ammonium salts and subsequent 
nucleophilic quench 
 
A flame dried Schlenk flask was charged with a solution of (+)-
BTM (0.2 equiv.), HOBt (1.0 equiv.), iPr2NH (1.4 equiv.) and 
MeCN (0.07 M) and cooled to −20 °C and stirred for 5 mins. The 
solution was treated with the requisite ammonium salt (1.0 
equiv.) and stirred for a further 16 h, after which the 
corresponding nucleophile (2.0 - 5.0 equiv.) was added and the 
reaction allowed to warm to rt and stirred for the time stated. The 
reaction was quenched with aq. 1 M NaOH (equal volume) and 
extracted with CH2Cl2 (3 × equal volume). The combined organic 
layers were washed with aq. 1 M NaOH (2 × equal volume), 
brine (equal volume), dried over MgSO4 and concentrated in 
vacuo. The residue was analysed by 1H NMR to determine dr, 
then purified by flash column chromatography to give the 
rearranged product. 
 
Ethyl (2S,3S)-2-(diallylamino)-3-phenylpent-4-enoate 22 
 
Following general procedure C, (E)-N,N-diallyl-N-(2-(4-
nitrophenoxy)-2-oxoethyl)-3-phenylprop-2-en-1-ammonium 
bromide (1.0 g, 2.11 mmol, 1.0 equiv.) was reacted with (+)-
BTM (107 mg, 0.42 mmol, 0.2 equiv.), HOBt (285 mg, 2.11 
mmol, 1.0 equiv.) and iPr2NH (413 µL, 2.95 mmol, 1.4 equiv.) in 
MeCN (30 mL), then quenched with NaOEt (1 M in EtOH, 10.6 
mL, 10.6 mmol, 5.0 equiv.) and stirred for a further 24 h at rt. 
Crude dr >95:5. The residue was purified by flash column 
chromatography on silica gel (5% EtOAc/hexanes) to give the 
title product (479 mg, 76%, >95:5 dr) as a colourless oil; HPLC 
analysis, Chiralpak AD-H (0.5% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 3.2 min, Minor 3.7 min, 97% 
ee; [α]
 +18.8 (c 1, CHCl3); υmax (film, cm−1) 2980, 1726, 1640, 
1445, 1417, 1246, 1152, 995, 916; 1H NMR (500 MHz, CDCl3) 
δH 1.33 (3H, t, J 7.1, OCH2CH3), 2.83 (2H, dd, J 14.5,8.3, 
NCHH), 3.37 (2H, ddt, J 14.5, 4.1, 1.9, NCHH), 3.76-3.85 (2H, 
m, C(2)H + C(3)H), 4.14-4.30 (2H, OCH2CH3), 4.88-5.16 (6H, 
m, C(5)H2 + diallyl-C(3)H2), 5.34-5.37 (2H, m, diallyl-C(2)H), 
5.92 (1H, dddd, J 17.1, 10.2, 7.0, 0.9, C(4)H), 7.13-7.19 (2H, m, 
ArH), 7.20-7.26 (1H, m, ArH), 7.26-7.35 (2H, m, ArH); 13C{1H} 
NMR (179 MHz, CDCl3) δC 14.7 (OCH2CH3), 50.4 (C(3)H), 53.2 
(NCH2), 60.1 (OCH2CH3), 65.4 (C(2)H), 116.7 (C(5)H2), 117.2 
(diallyl-C(3)H2), 126.5 (ArC(4)H), 128.3 (ArC(2,6)H), 128.5 
(ArC(3,5)H), 128.5 (ArC(2,6)H), 136.4 (diallyl-C(2)H), 138.7 
(C(4)H), 141.0 (ArC(1)), 171.5 (C=O); HRMS (ESI+) 
C19H26O2N+ [M+H]+ found: 300.1948, requires: 300.1958 (−3.4 
ppm). 
 
(2S,3S)-N-Benzyl-2-(diallylamino)-3-phenylpent-4-enamide 
29 
 
Following general procedure C, (E)-N,N-diallyl-N-(2-(4-
nitrophenoxy)-2-oxoethyl)-3-phenylprop-2-en-1-ammonium 
bromide (114 mg, 0.24 mmol, 1.0 equiv.) was reacted with (+)-
BTM (12 mg, 0.048 mmol, 0.2 equiv.), HOBt (6.4 mg, 0.048 
mmol, 0.2 equiv.) and iPr2NH (47 µL, 0.34 mmol, 1.4 equiv.) in 
MeCN (3.5 mL), then quenched with BnNH2 (131 µL, 1.20 
mmol, 5.0 equiv.) and stirred for a further 24 h. Crude dr 93:7. 
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The residue was purified by flash column chromatography on 
silica gel (0-2% Et2O/CH2Cl2) to give the title product (85 mg, 
98%, 92:8 dr) as a colourless oil; HPLC analysis, Chiralpak OJ-H 
(5% IPA/hexane, flow rate 1.5 mL/min, 211 nm, 40 °C) tR Major 
6.2 min, Minor 5.2 min, 84% ee; [α] +53.1 (c 1.0, CHCl3); υmax 
(film, cm−1) 3296, 2928, 1631, 1506, 1452, 1334, 1246, 1120, 
912; 1H NMR (500 MHz, CDCl3) δH 2.92 (2H, dd, J 14.6, 8.0, 
NCHH), 3.38-3.46 (2H, m, NCHH), 3.51 (1H, d, J 9.9, C(2)H), 
3.94-4.02 (1H, m, C(3)H), 4.51 (2H, dd, J 5.6, 2.9, PhCH2), 4.93-
5.16 (6H, m, C(5)H2 + diallyl-CH2), 5.45 (2H, dddd, J 16.8, 10.5, 
8.0, 4.4, diallyl-C(1)H), 5.95-6.06 (2H, m, C(4)H + NH), 7.14-
7.34 (10H, m, ArH); 13C{1H} NMR (75 MHz, CDCl3) δC 43.4 
(PhCH2), 49.7 (C(3)H), 53.5 (diallyl-C(1)H2), 66.7 (C(2)H), 
117.0 (C(5)H2 + diallyl-C(3)H2), 126.4 (C(3)Ar(C(4)H), 127.7 
(Ar(C(4)H), 128.2 (C(3)Ar(C(2,6)H), 128.3 (Ar(C(2,6)H), 128.6 
(C(3)Ar(C(3,5)H), 128.8 (Ar(C(3,5)H), 137.1 (diallyl-C(2)H), 
138.4 (C(3)ArC(1)),  139.0 (C(4)H), 141.5 (Ar(C(1)), 170.2 
(C=O); HRMS (NSI+) C24H29N2O+ [M+H]+ found: 361.2277, 
requires 361.2274 (+0.8 ppm).  
 
(2S,3S)-2-(Diallylamino)-3-phenylpent-4-en-1-ol 28 
 
Following general procedure C, with slight modification (E)-
N,N-diallyl-N-(2-(4-nitrophenoxy)-2-oxoethyl)-3-phenylprop-2-
en-1-ammonium bromide (114 mg, 0.24 mmol, 1.0 equiv.) was 
reacted with (+)-BTM (12 mg, 0.048 mmol, 0.2 equiv.), HOBt 
(32 mg, 0.24 mmol, 1.0 equiv.) and iPr2NH (47 µL, 0.34 mmol, 
1.4 equiv.) in MeCN, then concentrated in vacuo and the solvent 
switched to THF (3.5 mL, 2 cycles). The solution was cooled to 0 
°C and treated with LiAlH4 (1.0 M in THF, 0.48 mL, 0.48 mmol, 
2.0 equiv.) dropwise. The reaction was stirred for 1 h, quenched 
by the addition of aq. 1 M KOH (10 mL) and extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed 
with aq. 1 M KOH (2 × 10 mL), dried over MgSO4 then 
concentrated in vacuo. Crude dr >95:5. The residue was purified 
by flash coloumn chromatography on silica gel (0-10% 
Et2O/CH2Cl2) to give the title product (54 mg, 88%, >95:5 dr) as 
a colourless oil; HPLC analysis, Chiralpak OJ-H (0.5% 
IPA/hexane, flow rate 1.5 mL/min, 211 nm, 40 °C) tR Major 5.5 
min, Minor 4.5 min, 96% ee; [α]
 +27.3 (c 1.0, CHCl3); υmax 
(film, cm−1) 3420, 2924, 1601, 1415, 1265, 1045, 991, 914; 1H 
NMR (400 MHz, CDCl3) δH 2.70 (2H, dd, J 14.1, 8.0, NCHH), 
3.23 (2H, ddt, J 14.1, 4.4, 1.7, NCHH), 3.30 (1H, app. t, J 10.0, 
CHHOH), 3.37 (1H, td, J 9.5, 9.0, 4.1, C(2)H), 3.47 (1H, t, J 9.5, 
C(3)H), 3.63 (1H, dd, J 10.0, 4.1, CHHOH), 4.84-5.11 (6H, m, 
diallyl-C(3)H2 + C(5)H2), 5.64 (2H, dddd, 17.2, 10.2, 8.0, 4.8, 
diallyl-C(2)H), 5.79-6.01 (1H, m, C(4)H), 7.21-7.34 (5H, m, 
ArH); 13C{1H} NMR (100 MHz, CDCl3) δC 51.4 (C(3)H), 52.6 
(diallyl-C(1)H2), 60.3 (C(1)H2), 62.2 (C(2)H), 115.8 (C(5)H2), 
117.4 (diallyl-C(3)H2), 126.9 (ArC(4)H), 128.2 (ArC(2,6)H), 
128.8 (ArC(3,5)H), 137.0 (diallyl-C(2)H), 138.9 (C(4)H), 143.0 
(ArC(1)); HRMS (NSI+) C17H24NO+ [M+H]+ found: 258.1853, 
requires 258.1852 (+0.4 ppm). 
 
(2S,3S)-2-(Diallylamino)-3-phenyl-1-(pyrrolidin-1-yl)pent-4-
en-1-one 27 
 
Following general procedure C, (E)-N,N-diallyl-N-(2-(4-
nitrophenoxy)-2-oxoethyl)-3-phenylprop-2-en-1-ammonium 
bromide (114 mg, 0.24 mmol, 1.0 equiv.) was reacted with (+)-
BTM (12 mg, 0.048 mmol, 0.2 equiv.), HOBt (32 mg, 0.24 
mmol, 1.0 equiv.) and iPr2NH (47 µL, 0.34 mmol, 1.4 equiv.) in 
MeCN (3.5 mL), then quenched with pyrrolidine (100 µL, 1.20 
mmol, 5.0 equiv.) and stirred for a further 24 h at rt. Crude dr 
>95:5. The residue was purified by flash column chromatography 
on silica gel (0-5% Et2O/CH2Cl2) to give the title product (68 mg, 
87%, >95:5 dr) as a colourless oil; HPLC analysis, Chiralpak 
AD-H (5% IPA/hexane, flow rate 1.5 mL/min, 211 nm, 40 °C) tR 
Major 3.8 min, Minor 5.9 min, 98% ee; [α] +134.0 (c 1, 
CHCl3); υmax (film, cm−1) 2974, 1629, 1429, 1420, 1157, 991; 1H 
NMR (700 MHz, CDCl3) δH 1.76-1.93 (4H, m, C(3ʹ + 4ʹ)H2), 
2.96 (2H, dd, J 15.1, 7.9, NCHH), 3.36-3.45 (3H, m, NCHH 
+C(2ʹ)HH), 3.49 (2H, t, J 6.9, C(5ʹ)H2), 3.58 (1H, dt, J 9.8, 6.5, 
C(2ʹ)HH), 3.82-3.98 (2H, m, C(2)H + C(3)H), 4.84-5.09 (6H, m, 
C(5)H2 + diallyl-C(3)H2), 5.41 (2H, dddd, J 17.1, 10.2, 7.9, 4.2, 
diallyl-C(2)H), 5.90 (1H, ddd, J 17.0, 10.1, 7.7, C(4)H), 7.21 
(3H, tt, J 8.2, 1.5, ArH), 7.30 (2H, dd, J 8.6, 6.6, ArH); 13C{1H} 
NMR (179 MHz, CDCl3) δC 24.4 (C(4ʹ)H2), 26.4 (C(3ʹ)H2), 45.4 
(C(5ʹ)H2), 51.3 (C(3)H), 53.3 (diallyl-C(1)H2), 63.5 (C(2)H), 
116.1 (diallyl-C(3)H2), 116.9 (C(5)H2), 126.4 (ArC(4)H), 128.3 
(ArC(2,6)H), 128.8 (ArC(3,5)H), 137.9 (diallyl-C(2)H), 138.7 
(C(4)H), 141.4 (ArC(1)), 171.0 (C=O); HRMS (ESI+) 
C21H29ON2+ [M+H]+ found: 325.2265, requires: 325.2274 (−2.8 
ppm). 
 
Ethyl (2S,3S)-3-(2-bromophenyl)-2-(diallylamino)pent-4-
enoate 33 
 
Following general procedure C, (E)-N,N-diallyl-3-(2-
bromophenyl)-N-(2-(4-nitrophenoxy)-2-oxoethyl)prop-2-en-1-
ammonium bromide (0.3 g, 0.54 mmol, 1.0 equiv.) was reacted 
with (+)-BTM (27 mg, 0.11 mmol, 0.2 equiv.), HOBt (73 mg, 
0.54 mmol, 1.0 equiv.) and iPr2NH (105 µL, 0.76 mmol, 1.4 
equiv.) in MeCN (7.7 mL), then quenched with NaOEt (1 M in 
EtOH, 2.70 mL, 2.70 mmol, 5.0 equiv.) and stirred for a further 
24 h at rt. Crude dr 92:8. The residue was purified by flash 
column chromatography on silica gel (5% EtOAc/hexanes) to 
give the title product (173 mg, 85%, 92:8 dr) as a colourless oil; 
Enantiopurity determined after derivatisation to 38 and N-Boc 
protection 92% ee; [α] + 9.6 (c 1, CHCl3); υmax (film, cm−1) 
2980, 1728, 1638, 1472, 1244, 1177, 1153, 1020, 918; 1H NMR 
(500 MHz, CDCl3) δH 1.32 (3H, t, J 7.1, OCH2CH3), 2.79 2H, dd, 
J 14.4, 8.5, NCHH), 3.38 (2H, ddt, J 14.4, 4.0, 1.9, NCHH), 3.85 
(1H, d, J 11.6, C(2)H), 4.14-4.29 (2H, m, OCH2CH3), 4.47 (1H, 
dd, J 11.6, 8.0, C(3)H), 4.93-5.17 (6H, m, C(5)H2 + diallyl-
C(3)H2), 5.40 (2H, dddd, J 17.3, 11.3, 8.5, 4.0, diallyl-C(2)H), 
5.75 (1H, ddd, J 17.6, 10.1, 8.0, C(4)H), 7.05 (1H, ddd, J 8.1, 
7.2, 1.7, ArC(4)H), 7.15 (1H, dd, J 7.7, 1.7, ArC(5)H), 7.28 (1H, 
dd, J 7.7, 1.3, ArC(6)H), 7.53 (1H, dd, J 8.0, 1.3, ArC(3)H); 
13C{1H} NMR (126 MHz, CDCl3) δC 14.8 (OCH2CH3), 48.5 
(C(3)H), 53.3 (NCH2), 60.2 (OCH2CH3), 65.1 (C(2)H), 117.3 
(diallyl-C(3)H2), 117.6 (C(5)H2), 125.3 (ArC(2)-Br), 127.2 
(ArC(5)H, 127.8 (ArC(4)H), 129.7 (ArC(6)H, 132.9 (ArC(3)H), 
136.2 (diallyl-C(2)H), 137.3 (C(4)H), 139.8 (ArC(1)), 171.2 
(C=O); HRMS (ESI+) C19H25O2NBr+ [M+H]+ found: 378.1052, 
requires: 378.1063 (−2.9 ppm). 
 
Ethyl (2S,3S)-2-(diallylamino)-3-(4-nitrophenyl)pent-4-enoate 
32 
 
Following general procedure C, (E)-N,N-diallyl-3-(4-
nitrophenyl)-N-(2-(4-nitrophenoxy)-2-oxoethyl)prop-2-en-1-
ammonium bromide (0.2 g, 0.39 mmol, 1.0 equiv.) was reacted 
with (+)-BTM (20 mg, 0.08 mmol, 0.2 equiv.), HOBt (53 mg, 
0.39 mmol, 1.0 equiv.) and iPr2NH (76 µL, 0.55 mmol, 1.4 
equiv.) in MeCN (5.6 mL), then quenched with NaOEt (1 M in 
EtOH, 1.95 mL, 1.95 mmol, 5.0 equiv.) and stirred for a further 
24 h at rt. Crude dr 90:10. The residue was purified by flash 
column chromatography on silica gel (5% EtOAc/hexanes) to 
give the title product (92 mg, 69%, 90:10 dr) as a yellow oil; 
Enantiopurity determined after derivatisation to 39 and N-Boc 
protection, 96% ee; [α] +54.7 (c 1, CHCl3); υmax (film, cm−1) 
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2980, 1724, 1518, 1343, 1155, 920, 854; 1H NMR (500 MHz, 
CDCl3) δH 1.34 (3H, t, J 7.1, OCH2CH3), 2.81 (2H, dd, J 14.4, 
8.4, NCHH), 3.35 (2H, ddt, J 14.4, 4.0, 1.9, NCHH), 3.82 (1H, d, 
J 11.7, C(2)H), 3.98 (1H, dd, J 11.7, 7.9, C(3)H), 4.24 (2H, dddd, 
J 18.0, 10.8, 7.1, 3.7, OCH2CH3), 4.98-5.16 (6H, m, C(5)H2 + 
diallyl-C(3)H2), 5.36 (2H, dddd, J 16.9, 10.3, 8.3, 4.1, diallyl-
C(2)H), 5.86 (1H, ddd, J 17.0, 10.3, 7.9, C(4)H), 7.33 (2H, d, J 
8.8, Ar(2,6)H), 8.19 (2H, d, J 8.8, Ar(3,5)H); 13C{1H} NMR (126 
MHz, CDCl3) δC 14.7 (OCH2CH3), 50.1 (C(3)H), 53.1 (NCH2), 
60.4 (OCH2CH3), 64.9 (C(2)H), 117.9 (diallyl-C(3)H2), 118.2 
(C(5)H2), 123.6 (ArC(3,5)H), 129.4 (ArC(2,6)H), 135.6 (diallyl-
C(2)H), 137.1 (C(4)H), 146.7 (ArC(1)), 149.1 (ArC(4)-NO2), 
170.6 (C=O); HRMS (ESI+) C19H25O4N2+ [M+H]+ found: 
345.1802, requires: 345.1809 (−2.0 ppm). 
 
Ethyl (2S,3S)-3-(4-bromophenyl)-2-(diallylamino)pent-4-
enoate 34 
 
Following general procedure C, (E)-N,N-diallyl-3-(4-
bromophenyl)-N-(2-(4-nitrophenoxy)-2-oxoethyl)prop-2-en-1-
ammonium bromide (400 mg, 0.73 mmol, 1.0 equiv.) was reacted 
with (+)-BTM (37 mg, 0.15 mmol, 0.2 equiv.), HOBt (99 mg, 
0.73 mmol, 1.0 equiv.) and iPr2NH (142 µL, 1.02 mmol, 1.4 
equiv.) in MeCN (10.4 mL), then quenched with NaOEt (1 M in 
EtOH, 3.65 mL, 3.65 mmol, 5.0 equiv.) and stirred for a further 
24 h at rt. Crude dr 90:10. The residue was purified by flash 
column chromatography on silica gel (5% EtOAc/hexanes) to 
give the title product (213 mg, 77%, 91:9 dr) as a yellow oil; 
HPLC analysis, Chiralpak AD-H (0.5% IPA/hexane, flow rate 
1.5 mL/min, 211 nm, 40 °C) tR Major 3.2 min, Minor 3.9 min, 
96% ee; [α] +40.5 (c 1, CHCl3); υmax (film, cm−1) 2980, 1726, 
1489, 1173, 1153, 1011, 918; 1H NMR (500 MHz, CDCl3) δH 
1.30 (3H, t, J 7.1, OCH2CH3), 2.79 (2H, dd, J 14.4, 8.4, NCHH), 
3.33 (2H, ddt, J 14.4, 4.1, 1.9, NCHH), 3.67-3.81 (2H, m, C(2)H 
+ C(3)H), 4.13-4.26 (2H, m, OCH2CH3), 4.96-5.09 (6H, m, 
C(5)H2 + diallyl-C(3)H2), 5.38 (2H, dddd, J 16.5, 10.8, 8.4, 4.1, 
diallyl-C(2)H), 5.83 (1H, ddd, J 17.0, 10.2, 7.7, C(4)H), 7.02 
(2H, d, J 8.4, Ar(2,6)H), 7.41 (2H, d, J 8.4, Ar(3,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC 14.7 (OCH2CH3), 49.7 (C(3)H), 53.1 
(NCH2), 60.2 (OCH2CH3), 65.1 (C(2)H), 117.1 (C(5)H2), 117.5 
(diallyl-C(3)H2), 120.0 (ArC-Br), 130.3 (ArC(2,6)H), 131.3 
(ArC(3,5)H), 136.1 (diallyl-C(2)H), 138.1 (C(4)H), 140.1 
(ArC(1)), 171.2 (C=O); HRMS (ESI+) C19H25O2NBr+ [M+H]+ 
found: 378.1054, requires: 378.1063 (−2.4 ppm). 
 
Ethyl (2S,3S)-2-(diallylamino)-3-(4-fluorophenyl)pent-4-
enoate 31 
 
Following general procedure C, (E)-N,N-diallyl-3-(4-
nitrophenyl)-N-(2-(4-fluorophenoxy)-2-oxoethyl)prop-2-en-1-
ammonium bromide (400 mg, 0.82 mmol, 1.0 equiv.) was reacted 
with (+)-BTM (40 mg, 0.16 mmol, 0.2 equiv.), HOBt (111 mg, 
0.82 mmol, 1.0 equiv.) and iPr2NH (160 µL, 1.15 mmol, 1.4 
equiv.) in MeCN (12 mL), then quenched with NaOEt (1 M in 
EtOH, 4.10 mL, 4.10 mmol, 5.0 equiv.) and stirred for a further 
24 h at rt. Crude dr 94:6. The residue was purified by flash 
column chromatography on silica gel (5% EtOAc/hexanes) to 
give the title product (222 mg, 85%, 95:5 dr) as a colourless oil; 
HPLC analysis, Chiralpak AD-H (0.5% IPA/hexane, flow rate 
1.5 mL/min, 211 nm, 40 °C) tR Major 3.3 min, Minor 4.3 min, 
96% ee; [α]+14.8 (c 1, CHCl3); υmax (film, cm−1) 2980, 1726, 
1508, 1223, 1157, 918, 829; 1H NMR (300 MHz, CDCl3) δH 1.30 
(3H, t, J 7.1, OCH2CH3), 2.79 (2H, dd, J 14.5, 8.3, NCHH), 3.34 
(2H, ddt, J 14.5, 4.0, 1.9, NCHH), 3.65-3.84 (2H, m, C(2)H + 
C(3)H), 4.09-4.34 (2H, m, OCH2CH3), 4.86-5.14 (6H, m, C(5)H2 
+ diallyl-C(3)H2), 5.26-5.50 (2H, m, diallyl-C(2)H), 5.85 (1H, 
ddd, J 17.1, 10.2, 7.6, C(4)H), 6.98 (2H, t, J 8.7, Ar(3,5)H), 7.09 
(2H, ddt, 8.3, 5.2, 2.5, Ar(2,6)H); 19F{1H} NMR (272 MHz, 
CDCl3) δF −116.9 (ArF); 13C{1H} NMR (126 MHz, CDCl3) δC 
14.7 (OCH2CH3), 49.5 (C(3)H), 53.1 (NCH2), 60.2 (OCH2CH3), 
65.3 (C(2)H), 115.1 (d, 2JCF 21.2, ArC(3,5)H), 116.8 (C(5)H2), 
117.4 (diallyl-C(3)H2), 129.9 (d, 3JCF 7.8, ArC(2,6)H), 136.2 
(diallyl-C(2)H), 136.7 (d, 4JCF 3.2, ArC(1)), 138.5 (C(4)H), 161.6 
(d, 1JCF 244, ArC-F), 171.3 (C=O); HRMS (ESI+) C19H25O2NF+ 
[M+H]+ found: 318.1854, requires: 318.1864 (−3.1 ppm). 
 
Deallylation of Products 
 
General Procedure D: Bis-deallylation of α-N,N diallyl amino 
esters 
 
A flamed dried Schlenk tube was charged with Pd(dba)2 (0.1 
equiv.), dppb (0.1 equiv.) and thiosalicyclic acid (5.0 equiv.) 
under Ar. A solution of N,N-diallyl amino ester (1.0 equiv.) in 
degassed THF (0.1 M) was added and the resulting mixture 
heated to 60 °C under Ar for 3 h. Once complete the reaction was 
cooled to rt and aq. 1 M HCl and EtOAc added, the layers 
separated and the aqueous layer washed with EtOAc (2 × equal 
volume). The aqueous layer was then concentrated in vacuo to 
give the pure α-amino ester hydrochloride salt. 
 
General Procedure E: N-Boc protection of α-amino ester 
hydrochloride salts 
 
A solution of α-amino ester hydrochloride salt (1.0 equiv.) in 
CH2Cl2 (0.07 M) was treated with NEt3 (3.0 equiv.) and Boc2O 
(5.0 equiv.) and stirred for 16 h at room temperature. The 
resulting mixture was concentrated in vacuo, dissolved in MeOH 
(3 × equal volume) and treated with 4-DMAP (0.1 equiv.) and 
stirred for 3 h. Once complete the solution was concentrated in 
vacuo, dissolved in EtOAc (5 × equal volume) washed with aq. 1 
M HCl (equal volume) and brine (equal volume), dried over 
MgSO4 and concentrated in vacuo to give the N-Boc α-amino 
ester.  
 
Ethyl (2S,3S)-2-amino-3-phenylpent-4-enoate hydrochloride 
36 
 
Following general procedure D, Pd(dba)2 (19 mg, 0.033 mmol, 
0.1 equiv), dppb (14 mg, 0.033 mmol, 0.1 equiv.), thiosalicyclic 
acid (254 mg, 1.65 mmol, 5.0 equiv.) and ethyl (2S,3S)-2-
(diallylamino)-3-phenylpent-4-enoate (100 mg, 0.33 mmol, 1.0 
equiv.) were reacted in THF (3.3 mL) to give the title product as 
a colourless gum (65 mg, 77%, >95:5 dr); The corresponding free 
amine was prepared for HPLC analysis by dissolution in HPLC 
iPrOH and filtration through a pipette plug of K2CO3; HPLC 
analysis, Chiralpak AS-H (5% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 3.5 min, Minor 4.0 min, 94% 
ee; [α]
+59.2 (c 1, MeOH); υmax (film, cm−1) 3375, 2870, 1736, 
1587, 1495, 1219, 1043, 993, 858; 1H NMR (400 MHz, d4-
MeOH) δH 1.24 (3H, t, J 7.1, OCH2CH3), 3.88 (1H, t, J 8.4, 
C(3)H), 4.23 (2H, q, J 7.1, OCH2CH3), 4.36 (1H, d, J 8.4, 
C(2)H), 5.20-5.33 (2H, m, C(5)H2), 6.13 (1H, ddd, J 17.2, 9.9, 
9.1, C(4)H), 7.28-7.47 (5H, m, ArH); 13C{1H} (126 MHz, d4-
MeOH) δC 14.3 (OCH2CH3), 52.9 (C(3)H), 58.0 (C(2)H), 63.4 
(OCH2CH3), 119.9 (C(5)H), 129.2 (ArC(4)H), 129.2 
(ArC(3,5)H), 1303 (ArC(2,6)H), 136.1 (C(4)H), 138.7 (ArC(1)), 
169.4 (C=O); HRMS (ESI+) C13H18O2N+ [M]+ found: 220.1327, 
requires: 220.1332 (−2.3 ppm). 
 
Ethyl (2S,3S)-2-acetamido-3-phenylpent-4-enoate 55 
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A solution of ethyl (2S,3S)-2-amino-3-phenylpent-4-enoate 
hydrochloride (276 mg, 1.08 mmol, 1.0 equiv.) in dry CH2Cl2 (6 
mL) was treated with Et3N (300 µL, 2.15 mmol, 2.0 equiv.) and 
acetic anhydride (200 µL, 2.12 mmol, 2.0 equiv.) and stirred for 
16 h at room temperature. The reaction mixture was then diluted 
by the addition of EtOAc (50 mL). The resulting solution was 
washed with brine (20 mL), dried over MgSO4 and concentrated 
in vacuo. The crude residue was purified by Biotage® IsoleraTM 4 
[SNAP Ultra 25 g, 75 mL/min, PE:EtOAc (90:10 1 CV, 90:10 to 
40:60 10 CV, 40:60 1 CV)] to give the title product as a white 
solid (273 mg, 97%, >95:5 dr); HPLC analysis, Chiralpak AD-H 
(10% IPA/hexane, flow rate 0.7 mL/min, 211 nm, 30 °C) tR 
Minor 10.0 min, Major 12.2 min, 95% ee; [α]+89.8 (c 1, 
CHCl3), lit.15 [α]+77.3 (c 0.98, CHCl3); mp: 64-66 °C; 1H 
NMR (400 MHz, CDCl3) δH 1.21 (3H, t, J 7.1, OCH2CH3), 1.93 
(3H, s, C(O)CH3), 3.82 (1H, t, J 7.4, C(3)H), 4.13 (2H, q, J 7.1, 
OCH2CH3), 4.98 (1H, dd, J 8.7, 6.6, C(2)H), 5.15 – 5.23 (2H, m, 
C(5)H2), 5.72 (1H, d, J 8.7, NH), 6.01 – 6.12 (1H, m, C(4)H), 
7.18 – 7.34 (5H, ArH); 13C{1H} NMR (101 MHz, CDCl3) δC 14.2 
(OCH2CH3), 23.3 (C(O)CH3), 52.3 (C(3)H), 55.9 (C(2)H), 61.4 
(OCH2CH3), 117.9 (C(5)H2), 127.5 (ArC(4)H), 128.2 (ArCH), 
128.8 (ArCH), 136.3 (C(4)H), 138.9 (ArC(1)), 169.8 (C=O 
ester), 171.4 (NHC=O). Data consistent with literature.15  
 
Ethyl (2S,3S)-2-amino-3-(2-bromophenyl)pent-4-enoate 
hydrochloride 38 
 
Following general procedure D, Pd(dba)2 (16 mg, 0.027 mmol, 
0.1 equiv), dppb (12 mg, 0.027 mmol, 0.1 equiv.), thiosalicyclic 
acid (203 mg, 1.32 mmol, 5.0 equiv.) and ethyl (2S,3S)-3-(2-
bromophenyl)-2-(diallylamino)pent-4-enoate (100 mg, 0.27 
mmol, 1.0 equiv., 93:7 dr) were reacted in THF (2.7 mL) to give 
the title product as a colourless gum (44 mg, 49%, 93:7 dr); 
Enantiopurity determined after N-Boc protection, 92% ee; 
[α]
+23.1 (c 1, MeOH); υmax (film, cm−1) 3350, 2982, 1736, 
1470, 1242, 1219, 1022, 939, 854;1H NMR (500 MHz, d4-
MeOH) δH 1.17 (3H, t, J 7.2, OCH2CH3), 4.19 (2H, qd, J 7.2, 4.2, 
OCH2CH3), 4.36 (1H, dd, J 9.4, 7.2, C(3)H), 4.47 (1H, d, J 7.2, 
C(2)H), 5.29-5.43 (2H, m, C(5)H2), 6.13 (1H, ddd, J 16.7, 10.2, 
9.4, C(4)H), 7.26 (1H, ddd, J 8.0, 5.0, 4.0, Ar(5)H), 7.42 (1H, dd, 
J 4.0, 0.7, Ar(4)H), 7.68 (1H, dt, J 8.0, 0.9, Ar(6)H); 13C{1H} 
NMR (179 MHz, d4-MeOH) δC 14.2 (OCH2CH3), 51.5 (C(3)H), 
56.3 (C(2)H), 63.6 (OCH2CH3), 121.9 (C(5)H2), 125.4 (ArC(2)-
Br), 129.4 (ArC(5)H), 130.7 (ArC(4)H), 130.8 (ArC(6)H), 133.9 
(ArC(3)H), 134.8 (C(4)H), 138.0 (ArC(1)), 169.0 (C=O); HRMS 
(ESI+) C13H17O2N79Br+ [M]+ found: 298.0434, requires: 298.0437 
(−1.0 ppm). 
 
Ethyl (2S,3S)-2-amino-3-(4-nitrophenyl)pent-4-enoate 
hydrochloride 39 
 
Following general procedure D, Pd(dba)2 (8.4 mg, 0.015 mmol, 
0.1 equiv), dppb (6.4 mg, 0.015 mmol, 0.1 equiv.), thiosalicyclic 
acid (116 mg, 0.75 mmol, 5.0 equiv.) and ethyl (2S,3S)-3-(4-
nitrophenyl)-2-(diallylamino)pent-4-enoate (50 mg, 0.15 mmol, 
1.0 equiv., 90:10 dr) were reacted in THF (1.5 mL) to give the 
title product as a colourless gum (24 mg, 53%, 88:12 dr); 
Enantiopurity determined after N-Boc protection, 96% ee; [α] 
+93.6 (c 0.25, MeOH); υmax (film, cm−1) 3377, 2905, 1740, 1520, 
1346, 1225, 1111, 1014, 852; 1H NMR (500 MHz, d4-MeOH) δH 
1.24 (3H, t, J 7.1, OCH2CH3), 3.99-4.08 (1H, m, C(3)H), 4.25 
(2H, q, J 7.1, OCH2CH3), 4.51 (1H, d, J 7.9, C(2)H), 5.24-5.40 
(2H, m, C(5)H2), 6.14 (1H, ddd, J 16.7, 103, 9.2, C(4)H), 7.64 
(2H, d, J 8.7, Ar(2,6)H), 8.28 (2H, d, J 8.7 Ar(3,5)H); 13C{1H} 
NMR (126 MHz, d4-MeOH) δC 14.3 (OCH2CH3), 52.5 (C(3)H), 
57.6 (C(2)H), 63.7 (OCH2CH3), 121.5 (C(5)H2), 125.2 
(ArC(2,6)H), 130.6 (ArC(3,5)H), 134.6 (C(4)H), 146.4 
(ArC(1)), 149.1 (ArC(4)-NO2), 169.0 (C=O); HRMS (ESI+) 
C13H17O4N2+ [M]+ found: 265.1176, requires: 265.1183 (−2.6 
pm). 
 
Ethyl (2S,3S)-2-amino-3-(4-fluorophenyl)pent-4-enoate 
hydrochloride 37 
 
Following general procedure D, Pd(dba)2 (9.2 mg, 0.016 mmol, 
0.1 equiv), dppb (12.8 mg, 0.016 mmol, 0.1 equiv.), 
thiosalicyclic acid (122 mg, 0.75 mmol, 5.0 equiv.) and ethyl 
(2S,3S)-3-(4-fluorophenyl)-2-(diallylamino)pent-4-enoate (50 
mg, 0.16 mmol, 1.0 equiv., 94:6 dr) were reacted in THF (1.5 
mL) to give the title product as a oily yellow solid (46 mg, 
quant., 92:8 dr); Enantiopurity determined after N-Boc 
protection, 94% ee; [α]+40.8 (c 1, CHCl3); υmax (film, cm−1) 
3397, 2864, 1736, 1603, 1508, 1223, 1014, 934, 836; 1H NMR 
(400 MHz, d4-MeOH) δH 1.26 (3H, t, J 7.1, OCH2CH3), 3.86 (1H, 
t, J 8.4, C(3)H), 4.24 (2H, q, J 7.1, OCH2CH3), 4.35 (1H, d, J 8.4, 
C(2)H), 5.21-5.31 (2H, m, C(5)H2), 6.11 (1H, ddd, J 16.8, 10.3, 
9.0, C(4)H), 7.14 (2H, t, J 8.8, Ar(3,5)H), 7.38 (2H, dd, J 8.8, 
5.2, Ar(2,6)H); 19F{1H} NMR (376, d4-MeOH) δF −116.2 (ArF); 
13C{1H} NMR (126 MHz, d4-MeOH) δC 14.3 (OCH2CH3), 52.2 
(C(3)H), 58.0 (C(2)H), 63.5 (OCH2CH3), 117.1 (d, 2JCF 21.8, 
ArC(3,5)H), 120.0 (C(5)H2), 131.2 (d, 3JCF 8.2, ArC(2,6)H), 
134.8 (d, 4JCF 3.3, ArC(1)), 135.9 (C(4)H), 163.9 (d, 1JCF 246, 
ArC(4)-F), 169.4 (C=O); HRMS (ESI+) C13H17O2NF+ [M]+ 
found: 238.1232, requires: 238.1238 (−2.5 ppm). 
 
Ethyl (2S,3S)-3-(2-bromophenyl)-2-((tert-
butoxycarbonyl)amino)pent-4-enoate 56 
 
Following general procedure D ethyl (2S,3S)-2-amino-3-(2-
bromophenyl)pent-4-enoate hydrochloride (48 mg, 0.14 mmol, 
1.0 equiv.), NEt3 (58 µL, 0.42 mmol, 3.0 equiv.) and Boc2O (153 
mg, 0.7 mmol, 5.0 equiv.) were reacted in CH2Cl2 (2 mL) to give 
the title product as a yellow oil (40 mg, 72%, 88:12 dr); HPLC 
analysis, Chiralpak AD-H (2% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 12.4 min, Minor 9.4 min, 92% 
ee; [α]
+38.4 (c 1, CHCl3); υmax (film, cm−1) 3345, 2930, 1717, 
1506, 1368, 1161, 1022, 930; 1H NMR (500 MHz, CDCl3) δH 
1.20 (3H, t, J 7.1, OCH2CH3), 1.33 (9H, s, C(CH3)3), 4.06-4.18 
(2H, m, OCH2CH3), 4.26 (1H, t, J 8.9, C(3)H), 4.68 (1H, t, J 8.9, 
C(2)H), 4.95 (1H, d, J 9.3, NH), 5.13-5.24 (2H, m, C(5)H2), 6.01 
(1H, ddd, J 16.9, 10.2, 8.6, C(4)H), 7.03-7.15 (1H, m, ArH), 
7.25-7.34 (2H, m, ArH), 7.56 (1H, d, J 8.0, ArH); 13C{1H} NMR 
(126 MHz, CDCl3) δC 14.1 (OCH2CH3), 28.2 (C(CH3)3), 51.2 
(C(3)H), 56.8 (C(2)H), 61.2 (OCH2CH3), 80.0 (C(CH3)3), 118.6 
(C(5)H2), 125.1 (ArC(2)-Br), 127.6 (ArC(5)H), 128.6 (ArC(4)H), 
129.2 (ArC(6)H), 133.1 (ArC(3)H), 135.5 (C(4)H), 138.4 
(ArC(1)), 154.9 (NC=O), 171.5 (C=O); HRMS (ESI+) 
C18H24O4NBrNa+ [M+Na]+ found: 420.0773, requires: 420.0781 
(−1.9 ppm).  
 
Ethyl (2S,3S)-2-((tert-butoxycarbonyl)amino)-3-(4-
fluorophenyl)pent-4-enoate 57 
 
Following general procedure D ethyl (2S,3S)-2-amino-3-(4-
fluorophenyl)pent-4-enoate hydrochloride (46 mg, 0.16 mmol, 
1.0 equiv.), NEt3 (67 µL, 0.48 mmol, 3.0 equiv.) and Boc2O (174 
mg, 0.8 mmol, 5.0 equiv.) were reacted in CH2Cl2 (2.3 mL) to 
give the title product as a colourless oil (24 mg, 45%, >95:5 dr); 
HPLC analysis, Chiralpak AD-H (5% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 7.4 min, Minor 5.6 min, 94% 
ee; [α]
+44.7 (c 1, CHCl3); υmax (film, cm−1) 3367, 2980, 2929, 
1715, 1510, 1357, 1224, 1161, 1024, 835; 1H NMR (400 MHz, 
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CDCl3) δH 1.23 (3H, J 7.1, OCH2CH3), 1.40 (9H, s, C(CH3)3), 
3.79 (1H, t, J 7.5, C(3)H), 4.14 (2H, qd, J 7.1, 1.1, OCH2CH3), 
4.59-4.71 (1H, m, C(2)H), 4.88 (1H, d, J 9.2, NH), 5.11-5.27 
(2H, m, C(5)H2), 6.07 (1H, ddd, J 16.9, 10.3, 8.3, C(4)H), 7.03 
(2H, t, J 8.7, Ar(3,5)H), 7.19 (2H, dd, J 8.7, 5.4, Ar(2,6)H); 
19F{1H} NMR (376 MHz, CDCl3) δF −115.5 (ArF); 13C{1H} 
NMR (126 MHz, CDCl3) δC 14.3 (OCH2CH3), 28.4 (C(CH3)3), 
51.8 (C(3)H), 57.5 (C(2)H), 61.4 (OCH2CH3), 80.2 (C(CH3)3), 
115.6 (d, 2JCF 21.3, ArC(3,5)H), 118.0 (C(5)H2), 130.0 (d, 3JCF 
7.9, ArC(2,6)H), 134.8 (d, 3JCF 2.4, ArC(1)), 136.4 (C(4)H), 
155.3 (NC=O), 162.1 (d, 1JCF 246, ArC(4)-F), 171.5 (C=O); 
HRMS (ESI+) C18H24O4NFNa+ [M+Na]+ found: 360.1575, 
requires: 360.1582 (−1.9 ppm). 
 
Ethyl (2S,3S)-2-((tert-butoxycarbonyl)amino)-3-(4-
nitrophenyl)pent-4-enoate 58 
 
Following general procedure D ethyl (2S,3S)-2-amino-3-(4-
nitrophenyl)pent-4-enoate hydrochloride (24 mg, 0.08 mmol, 1.0 
equiv.), NEt3 (33 µL, 0.24 mmol, 3.0 equiv.) and Boc2O (87 mg, 
0.40 mmol, 5.0 equiv.) were reacted in CH2Cl2 (1.1 mL) to give 
the title product as a colourless oil (22 mg, 76%); 
HPLC analysis, Chiralpak IB (1% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 10.0 min, Minor 8.7 min, 96% 
ee; [α]
+52.7 (c 1, CHCl3); υmax (film, cm−1) 3360, 2980, 1736, 
1715, 1522, 1346, 1163, 1024, 855;1H NMR (500 MHz, CDCl3) 
δH 1.21 (3H, t, J 7.1, OCH2CH3), 1.37 (9H, s, C(CH3)3), 3.88 (1H, 
t, J 7.8, C(3)H), 4.13 (2H, qd, J 7.1, 1.3, OCH2CH3), 4.71 (1H, t, 
J 7.8, C(2)H), 4.96 (1H, d, J 9.2, NH), 5.10-5.33 (2H, m, 
C(5)H2), 6.05 (1H, ddd, J 16.9, 10.2, 8.5, C(4)H), 7.41 (2H, d, J 
8.6, Ar(2,6)H), 8.18 (2H, d, J 8.6, Ar(3,5)H); 13C{1H} NMR (126 
MHz, CDCl3) δC 14.3 (OCH2CH3), 28.3 (C(CH3)3), 52.8 (C(3)H), 
57.4 (C(2)H), 61.7 (OCH2CH3), 80.5 (C(CH3)3), 119.5 (C(5)H2), 
123.8 (ArC(2,6)H), 129.4 (ArC(3,5)H), 134.9 (C(4)H), 147.1 
(ArC(1)), 147.2 (ArC(4)-NO2), 155.2 (NC=O), 171.0 (C=O); 
HRMS (ESI+) C18H24O6N2Na+ [M+Na]+ found: 387.1521, 
requires: 387.1532 (−1.4 ppm). 
 
Ethyl (2S,3S)-2-(allylamino)-3-phenylpent-4-enoate 42 
 
A flame dried two-necked flask was charged with Pd(dba)2 (58 
mg, 0.1 mmol, 0.1 equiv.), dppb (43 mg, 0.1 mmol, 0.1 equiv.) 
and thiosalicylic acid (184 mg, 1.2 mmol, 1.2 equiv.). A solution 
of ethyl (2S,3S)-2-(diallylamino)-3-phenylpent-4-enoate (300 
mg, 1.0 mmol, 1.0 equiv.) in degassed THF (10 mL) was added 
via syringe. The resulting solution was heated at reflux for 16 h, 
once complete the reaction was cooled to rt and treated with aq. 1 
M HCl (20 mL) and EtOAc (20 mL). The layer separated and the 
organic layer extracted with aq. 1 M HCl (2 × 20 mL). The 
combined aqueous layers were basified to ~pH 14 with aq. 2 M 
NaOH, then extracted with EtOAc (5 × 30 mL), the organics 
combined, washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column 
chromatography (5% EtOAc/PE) to give the title product as a 
colourless oil (118 mg, 46%); [α]+56.9 (c 1, CHCl3); υmax 
(film, cm−1) 3335, 2980, 1728, 1640, 1454, 1178, 1152, 1024, 
993, 918; 1H NMR (500 MHz, CDCl3) δH 1.21 (3H, t, J 7.1, 
OCH2CH3), 3.05 (1H, ddt, J 14.0, 6.5, 1.4, NCHH), 3.23 (1H, 
ddt, J 14.0, 5.6, 1.4, NCHH), 3.57-3.65 (2H, m, C(2)H + C(3)H), 
4.13 (2H, qd, J 7.1, 3.8, OCH2CH3), 5.01-5.19 (4H, m, C(5)H2 + 
NCH2CHCH2), 5.74 (1H, dddd, J 16.9, 10.2, 6.5, 5.7, NCH2CH), 
6.03-6.17 (1H, m, C(4)H), 7.19-7.25 (3H, m, ArH), 7.27-7.33 
(2H, m, ArH); 13C{1H} NMR (126 MHz, CDCl3) δC 14.3 
(OCH2CH3), 50.9 (NCH2), 53.6 (C(3)H), 60.7 (OCH2CH3), 65.3 
(C(2)H), 116.9 (C(5)H), 117.2 (NCH2CHCH2), 127.1 (ArC(4)H), 
128.2 (ArC(2,6)H), 128.7 (ArC(3,5)H), 136.2 (NCH2CH), 137.6 
(C(4)H), 140.3 (ArC(1)), 173.9 (C=O); HRMS (ESI+) 
C16H22O2N+ [M+H]+ found: 260.1638, requires: 260.1645 (−2.7 
ppm). 
 
Ethyl (2S,3S)-2-(allyl(benzyl)amino)-3-phenylpent-4-enoate 
43 
 
A solution of ethyl (2S,3S)-2-(allylamino)-3-phenylpent-4-enoate 
(202 mg, 0.78 mmol, 1.0 equiv.) in MeCN (11.2 mL), was treated 
with K2CO3 (215 mg, 1.56 mmol, 2.0 equiv.), KI (26 mg, 0.156 
mmol, 0.2 equiv.), and benzyl bromide (140 µL, 1.17 mmol, 1.5 
equiv.), the resulting solution was heated at reflux for 16 h. Once 
complete the reaction was cooled to rt, and aq. 1 M NaOH (20 
mL) and CH2Cl2 (20 mL) added, the layers separated and the 
aqueous layer extracted with CH2Cl2 (2 × 20 mL). The combined 
organic layers were washed with brine (50 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography (1-10% EtOAc/PE) to give the title 
product as a colourless oil (233 mg, 86%, 94:6 dr); [α]−6.1 (c 
1, CHCl3); υmax (film, cm−1) 2978, 1726, 1495, 1454, 1248, 1173, 
1153, 1136, 1028, 970; 1H NMR (500 MHz, CDCl3) δH 1.35 (3H, 
t, J 7.1, OCH2CH3), 2.82 (1H, dd, J 14.2, 8.7, NCHH), 3.27 (1H, 
d, J 14.1, PhCHH), 3.31 (1H, ddt, J 14.2, 4.0, 1.9, NCHH), 3.73 
(1H, d, J 11.6, C(2)H), 3.86 (1H, dd, J 11.6, 8.1, C(3)H), 3.95 
(1H, d, J 14.1, PhCHH), 4.18-4.32 (2H, m, OCH2CH3), 4.94-5.11 
(4H, m, C(5)H2 + NCH2CHCH2), 5.47 (1H, dddd, J 17.0, 10.3, 
8.7, 4.0, NCH2CH), 5.83 (1H, ddd, J 17.0, 10.2, 8.1, C(4)H), 
6.69-6.84 (2H, m, ArH), 7.03-7.08 (2H, m, ArH), 7.10-7.18 (3H, 
m, ArH), 7.22-7.32 (3H, m, ArH); 13C{1H} NMR (126 MHz, 
CDCl3) δC 14.8 (OCH2CH3), 50.3 (C(3)H), 53.4 (NCH2), 54.0 
(PhCH2), 60.1 (OCH2CH3), 65.1 (C(2)H), 116.7 (C(5)H2), 117.7 
(NCH2CHCH2), 126.6 (ArCH), 126.8 (ArCH), 128.0 (ArCH), 
128.4 ( rCH), 128.7 (ArCH), 128.9 (ArCH), 136.2 (NCH2CH), 
138.7 (C(4)H), 139.3 (C(3)ArC(1)), 140.7 (ArC(1)), 171.3 
(C=O); HRMS (ESI+) C23H28O2N+ [M+H]+ found: 350.2106, 
requires: 350.2115 (−2.6 ppm).  
 
Ethyl (2S,3S)-1-benzyl-3-phenyl-1,2,3,6-tetrahydropyridine-
2-carboxylate 44 
 
A two-neck flask equipped with a reflux condenser with charged 
with p-TsOH (191 mg, 1.01 mmol, 1.5 equiv.) followed by a 
solution of ethyl (2S,3S)-2-(allyl(benzyl)amino)-3-phenylpent-4-
enoate (233 mg, 0.67 mmol, 1.0 equiv., 94:6 dr) in degassed 
PhMe (67 mL), the solution was heated to 80 °C and stirred until 
full dissolution. After which the reaction was treated with 
Hoveyda-Grubbs 2nd generation catalyst (21 mg, 0.034 mmol, 5 
mol%) and the reaction mixture stirred at 80 °C for 16 h. Once 
complete by TLC, the reaction was cooled to rt and concentrated 
in vacuo, CH2Cl2 (50 mL) and aq. 1 M NaOH (50 mL) were 
added the layers separated and the aqueous layer extracted with 
CH2Cl2 (2 × 50 mL). The combined organic layers were washed 
with brine (50 mL) dried over MgSO4 and concentrated in vacuo. 
The residue was purified by Biotage® IsoleraTM 4 [SNAP Ultra 
10 g,36 mL/min, PE:EtOAc (99:1 1 CV, 99:1 to 90:10 10 CV, 
80:20 2 CV)] to give the title product as a yellow oil (161 mg, 
75%, 92:8 dr); [α] −127.1 (c 1, CHCl3); υmax (film, cm−1) 2978, 
1728, 1493, 1452, 1177, 1144, 1029, 845; 1H NMR (500 MHz, 
CDCl3) δH 0.81 (3H, t, J 7.1, OCH2CH3), 3.26 (1H, ddt, J 17.0, 
4.4, 2.4, NCHH), 3.57 (1H, ddt, J 17.0, 3.8, 2.4, NCHH), 3.62-
3.81 (4H, m, OCH2CH3 + C(3)H + PhCHH), 3.84, (1H, d, J 6.9, 
PhCHH), 4.00-4.08 (1H, m, C(2)H), 5.85 (1H, dq, J 10.2, 2.4, 
C(5)H), 5.99 (1H, ddt, J 10.2, 4.1, 2.5, C(4)H), 7.15-7.24 (3H, m, 
ArH), 7.25-7.31 (3H, m, ArH), 7.31-7.39 (4H, m, ArH); 13C{1H} 
NMR (126 MHz, CDCl3) δC 13.9 (OCH2CH3), 44.1 (C(2)H), 48.6 
(NCH2), 59.5 (PhCH2), 60.2 (OCH2CH3), 64.7 (C(3)H), 124.9 
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(C(5)H), 126.9 (C(4)H), 127.0 (ArC(4)H), 127.4 (ArC(4)H), 
128.3 (ArCH), 128.5 (ArCH), 128.7 (ArCH), 129.0 (ArCH), 
138.2 (ArC(1)), 140.4 (ArC(1)), 170.7 (C=O); HRMS (ESI+) 
C21H24O2N+ [M+H]+ found: 322.1795, reuiqres: 322.1802 (−2.2 
ppm). 
 
Ethyl (2S,3S)-3-phenylpiperidine-2-carboxylate 45 
 
A solution of ethyl (2S,3S)-1-benzyl-3-phenyl-1,2,3,6-
tetrahydropyridine-2-carboxylate (143 mg, 0.45 mmol, 1.0 
equiv., 92:8 dr) in EtOAc (4.5 mL) was treated with AcOH (27 
µL, 0.45 mmol, 1.0 equiv.) and Pd/C (47 mg, 10% wt., 0.045 
mmol, 0.1 equiv.). The resulting suspension was degassed with 
H2 for 15 min, then left stirring under an atmosphere of H2 
(balloon, 1 atm) for 48 h at rt. The reaction was diluted with 
EtOAc (30 mL), filtered through Celite® (eluent EtOAc), washed 
with aq. sat. NaHCO3 (30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by flash 
column chromatography (10-15% Et2O/CH2Cl2) to give the 
product as a colourless oil (63 mg, 60%, >95:5 dr); HPLC 
analysis, Chiralpak AS-H (1% IPA/hexane, flow rate 1.5 
mL/min, 211 nm, 40 °C) tR Major 3.7 min, Minor 3.4 min, 94% 
ee; 	[α]

 +11.0 (c 1, CHCl3); υmax (film, cm−1) 3348, 2932, 1728, 
1493, 1452, 1370, 1246, 1200, 1179, 1128, 1032, 862; 1H NMR 
(500 MHz, CDCl3) δH 0.94 (3H, t, J 7.1, OCH2CH3), 1.52 (1H, 
ddp, J 14.5, 7.3, 3.8, C(6)HH), 1.78 (1H, dddt, J 12.8, 9.0, 7.7, 
3.7, C(6)HH), 1.89 (1H, ddt, J 13.2, 8.8, 4.3, C(5)HH), 1.98 (1H, 
br. s, NH), 2.11 (1H, dtd, J 13.6, 7.1, 3.7, C(5)HH), 2.82 (1H, 
ddd, J 11.6, 7.9, 3.6, C(4)HH), 3.20-3.34 (2H, m, C(3)H + 
C(4)HH), 3.82 (1H, d, J 4.5, C(2)H), 3.92 (2H, qd, J 7.1, 3.0, 
OCH2CH3), 7.12-7.21 (1H, m, Ar(4)H), 7.22-7.31 (2H, m, 
Ar(2,6)H), 7.40-7.48 (2H, m, Ar(3,5)H); 13C{1H} NMR (126 
MHz, CDCl3) δC 14.0 (OCH2CH3), 23.3 (C(6)H2), 28.9 (C(5)H2), 
42.2 (C(3)H), 44.5 (C(4)H2), 60.3 (OCH2CH3), 61.5 (C(2)H), 
126.3 (ArC(4)H), 128.1 (ArC(2,6)H), 128.7 (ArC(3,5)H), 142.7 
(ArC(1)), 172.7 (C=O); HRMS (ESI+) C14H20O2N+ [M+H] found: 
234.1483, requires: 234.1489 (−2.6 ppm). 
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